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1. APIs 
1.1 Introduction 
“Any substance used in a finished pharmaceutical product 
(FPP), intended to furnish pharmacological activity or to 
otherwise have direct effect in the diagnosis, cure, 
mitigation, treatment or prevention of disease, or to have 
direct effect in restoring, correcting or modifying 
physiological functions in human beings.”             
Definition of API by the World Health Organization[1.1] 
APIs (Active Pharmaceutical Ingredients) are a very important class of 
chemicals for their fundamental role in the human health. They are the key 
compound in pharmaceutical formulations, due to their bioactivity that can 
be exploited to cure several diseases. For this reason, APIs have an 
immense market value related to their industrial production and 
commercialisation. 
 
Figure 1.1 - Global market of APIs 
Over the last few decades, the global market of Active Pharmaceutical 
Ingredients has undergone to an exponential growth (Figure 1.1), thanks to 
the increased use of drugs for the treatment of diseases. The major factors 
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that govern the market are the rising prevalence of diseases like 
cardiovascular condition, diabetes and lifestyle diseases, cancer and 
infections.[2.1] 
The global API market is anticipated to exhibit an annual growth rate of 6.8 
% in the forecast period (2018 – 2024), with the surpass of US $ 274.9 
billion value in 2024.[3.1] 
The pharmaceutical industries play an important and complex competition 
in this fields, either for the discovery of new API or for the research and 
development of new syntheses for existing drugs, improving the process 
design, reducing the costs of the production and increasing the quality 
standard. To keep up with this competition, the pharmaceutical industries 
are expanding by establishing most of their productions in the Asian and 
Pacific region. Lower production costs in China and India have stimulated 
the increase of the manufacturing of APIs in these regions. 
Another important field is represented by High Potency APIs, active 
ingredients with therapeutic daily dose much smaller than traditional 
APIs,[4.1] which are in rising demand by pharmaceutical manufacturers. 
Research and development departments are focusing heavily on the field of 
oncology. The IMS institute of healthcare informatics estimated that in 2016 
more than 550 drugs were under development for cancer treatment. 
Moreover, 70 new oncology treatments reached in the market between 
2010 and 2015.[3.1] 
 
1.2 Intellectual property 
APIs are almost always protected by strong intellectual property (IP), 
allowing the owners of the newly invented drug to have a complete but 
temporary exclusivity in terms of use, production and commercialization. 
The patent, as it is a technical-legal document, must be written in one of the 
languages recognized by the jurisdiction to which it was deposited. 
In addition to individual states, the patent application can be filed under 
international conventions, like the Patent Cooperation Treaty (PCT, Figure 
2.1) or the European Patent Convention (EPC, Figure 3.1).[5.1] 
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Figure 2.1 - Patent Cooperation Treaty 
After the initial filing of the patent there is a period, generally 18 months, in 
which the patent application is secreted by the receiving office, the latter 
operating a thorough examination of the novelty of the invention. At the end 
of this period, a publication number is assigned together with the 
publication date. 
Another crucial step is represented by the concession of the patent which, 
in most cases, does not take place before 3 years from the filing of the 
patent application. 
The inventors and the owner are two legally distinct entities that only 
sometimes coincide. While the inventors are necessarily real persons, as 
those who have achieved the invention object of the patent, the owners are 
very often juridical persons, mostly employers of the inventors. 
The first part of a patent is represented by the abstract, a brief summary 
consisting in a synthetic description of the invention. It focuses on the 
advantages that the inventive solution achieves. 
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An important part of a patent are the claims, defining concisely the scope of 
protection required by the patent owner. In the case of chemical and 
chemical-pharmaceutical fields, the patents first report, in the main claim, 
the starting materials and the synthetic steps strictly necessary to reach the 
product. In the subsequent claims, the optimal reaction conditions (e.g. 
temperature, nature of solvents, ratio of the chemicals, the eventual 
presence of a catalyst) are specified.[4.1] 
 
Figure 3.1 - European Patent Convention 
The patent for an invention has a duration of 20 years, starting from the 
date of patent application filing. Extension of the duration of the patent is 
provided for those inventions in which the placing on the market is 
significantly delayed by administrative procedure, as in the case of Active 
Pharmaceutical Ingredients. The extension of the duration of the patents is 
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permitted by a SPC (Supplementary Protection Certificate), which extends 
the validity to a maximum of 5 years.[6.1] 
Patents in chemical and chemical-pharmaceutical fields may be classified 
as product patents and process patents.  
 
1.2.1 Product patents 
Product patents are the first to be registered because they cover the 
structure of the new molecule, for which the biological activity must be 
demonstrated. Moreover, the molecule, object of the patent, must be 
synthesized or isolated by man. These patents are applied to any form of 
the drug, whether it is formulated as a tablet, capsule, cream or other final 
dosage forms. 
The new compound must be defined by using the general structure 
formulas. These include all the possible equivalent substituents, in a 
specific position on a basic chemical structure (the “skeleton” of the 
molecule). In order to create a valid patent for a product it is necessary, in 
addition to the structural formula, also to describe the synthesis, isolation or 
the purification of the aforementioned product.[6.1] 
Product patents have 20 years of validity and cannot be subject to renewal 
when their expiry dates. During this period only the inventor of the new 
molecule, except for concessions to third parts, can use, produce, 
commercialize and import the API.  
After the expiration date, the other competitors can start using and selling 
the molecule object of the patent. 
 
1.2.2 Process patent 
Process patents are related to the other type of patents but refer to the 
synthesis/production process employed for the preparation of the 
commercially available speciality, even if the Active Pharmaceutical 
Ingredient is not patentable because it is already known.[6.1] 
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These documents follow the same rules as the product patent: 20 years of 
validity and exclusivity of the inventor, no renewability by the SPC. 
When the product patent expires, the API can be produced freely but if a 
process patent is still operating on the original synthesis, the latter cannot 
be pursued. This leads to a very active research of alternative synthetic 
routes for the preparation of the API.  
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2. Outline of the thesis 
The PhD activity was funded by Chemelectiva S.r.l., a pharmaceutical 
company located in Novara. The activity of Chemelectiva is focused on the 
research of alternative and efficient synthesis of APIs, for which 
product/process patents are no longer valid or they are about to expire. 
These alternative syntheses must satisfy requirements:  
- Efficiency: related to the global yield of the entire protocol of 
synthesis; 
 
- Innovation: the synthetic route must have some synthetic strategy 
not used in the prior art; 
 
- Practicality: all the steps must be executed with easy operations and 
mild conditions; 
 
- Industrial scalability: all the operations and results must be the same 
obtained in laboratory scale, without any significant modification of 
the process; 
 
- Use of commercially available and cheap starting materials: for not 
having difficulty in finding raw materials and to lower costs of the 
final API. 
 
During the PhD, the work was based on APIs selected according to these 
parameters. In detail, the molecules selected for the research of alternative 
syntheses was: 
- vildagliptin, an important drug for the treatment of type 2 diabetes 
mellitus, object of the first year of the PhD; 
 
- fexofenadine hydrochloride, used on a large scale as a therapy for 
allergic rhinitis (second year of the PhD); 
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- ravidasvir hydrochloride, a novel API, not yet approved, for the 
treatment of chronic hepatitis C, studied during the last year of the 
PhD. 
The aim of this work is to designing alternative preparations for these 
selected APIs (Figure 1.2), optimising all the synthetic steps by adjusting 
reactions conditions and maximizing the yield of the processes and finally 
scaling up the whole syntheses to hundred-grams scale, for introduction of 
the processes to the industrial scale. 
 
Figure 1.2 - Selected APIs for the PhD work  
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3. Vildagliptin 
Vildagliptin 1.3 is an important Active Pharmaceutical Ingredient for the 
treatment of type 2 diabetes mellitus (T2DM). 
During the first year of the PhD, the work was focused on the research & 
development of a new synthetic strategy for the preparation of vildagliptin 
(Figure 1.3) and subsequent scale up of the process.  
 
Figure 1.3 - Vildagliptin 
 
3.1 Type 2 diabetes mellitus 
Diabetes mellitus (DM) is a syndrome of disordered metabolism leading to 
a very high blood levels of glucose (hyperglycemia). There are two most 
common forms of diabetes: type 1 diabetes mellitus and type 2 diabetes 
mellitus (T1DM, T2DM). T1DM is characterized by a diminished production 
of insulin (mediated by pancreatic -cells), while T2DM arises subsequently 
to a reduction of insulin secretion from -cells and an impaired response to 
insulin by peripheral tissues, such as muscles adipose and liver.[1.3] 
In 2012 DM affects about 370 million people worldwide with more than 90% 
of these cases diagnosed as T2DM. Due to the graving burden of diabetes 
in developing counties, the number of affected people is estimated to 
increase to approximately 550 million adults by 2030.[2.3] 
N
H
OH
N
O CN
1.3
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Figure 2.3 - Pathophysiology of T2DM 
Diabetes mellitus leads to hyperglycemia, excessive urine production, 
increased fluid intake, compensatory thirst, unexplained weight loss, letargy 
and changes of energy metabolism.[1.3]  
In addition, an important role is played by the hormones glucagon-like 
peptide 1 (GLP-1) and glucose-depedent insulinotropic peptide (GIP), 
responsible for the incretin effect. It is a phenomenon whereby insulin 
secretion increase in response to the ingestion of food and governing blood 
glucose levels.[2.3] 
 
3.2 Gliptins - Drugs for the treatment of T2DM 
A new class of oral antidiabetic drugs, for the treatment of type 2 diabetes 
mellitus, is represented by gliptins (Figure 3.3). These oral hypoglycemic 
agent are inhibitors of the enzyme dipeptidyl peptidase-IV (DPP-IV). This 
enzyme inhibits the incretin peptides GLP-1 and GIP, obtaining a diminution 
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of the insulin release and an increase of glycemia. By inhibiting DPP-IV, 
gliptins can stimulate the quantity of insulin released and decrease the 
glucose blood level.[3.3] 
 
Figure 3.3 - Gliptins 
Vildagliptin is a reversible inhibitor of dipeptidyl peptidase-IV and it is widely 
used for its high selectivity. The inhibition of the enzyme is attributable to 
the presence of the (2S)-cyanopyrrolidine moiety, known to be a mimic of 
the proline contained in the aminoacidic sequence of the incretin 
hormones.[4.3,5.3,6.3] This proline mimic group is shared with other gliptins like 
saxagliptin and anagliptin. The nitrile group is very important for the 
chemical stability, allowing oral administration of these drugs, and for the 
nanomolar-level inhibition of the DPP-IV.  
A portion of the patients affected by type 2 diabetes mellitus (~9%) are 
intolerant to the other classes of drugs used in a large scale (metformin, 
glibenclamide). The treatment with vildagliptin implies slightly higher costs 
than those using metformin or sulfonilureas, but provides an important 
economic impact in the treatment of the adverse effects (heart failure and 
severe hypoglicemic attacks).[7.3] 
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3.3 Results and discussion 
The molecule of vildagliptin 1.3 (Scheme 1.3) includes an 1-
hydroxyadamantane substructure bearing in position 3 a secondary amino 
group. The latter is connected to a (2S)-cyanopyrrolidine by a C2-linker 
moiety (acetyl). Retrosynthetic approaches to vildagliptin are based on a 
common strategy, starting with proline derivatives 2.3. By acylation of the 
nitrogen atom of the proline residue, the C2-linker was introduced (3.3) and, 
after dehydration of the prolinamide moiety (to give the compound 4.3), 3-
amino-1-adamantanol 5.3 was connected to give the final API. The last 
reaction relies on the presence a suitable leaving group placed on the distal 
carbon of the C2-linker moiety. 
 
Scheme 1.3 - previous syntheses of vildagliptin 
The reported syntheses differ in the specific proline derivative used as 
starting materials. L-Prolinamide (R = -CONH2) is the substrate of choice in 
the first reaction (acylation step) because it is commercially available in the 
desired enantiomerically pure form.[8.3,9.3,10.3] L-Proline and its methyl ester 
(R = -COOH, -COOMe) are valid alternative raw materials, provided that, 
after the acylation step, the carboxylate/carboxylic group is converted to the 
primary amide and then to the nitrile.[11.3,12.3] The preferred compound may 
be prolinonitrile (R = -CN) because it does not require a dehydration step. 
Since this compound is quite expensive and it is commercially available 
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only as the Boc-protected derivative (additional deprotection is required), it 
is not convenient as a starting material the preparation of vildagliptin. 
Existing synthetic protocols for the acylation of the chosen proline 
derivatives rely on the use of 2-chloroacetyl chloride,[8.3,13.3] or alternative 
acylating agents (X1 = -Br, -I, -OTs, -ONs, -OTf and X2 = -Br, -I, -OH, -
OSO2(C1-8)alkyl, -OSO2(aryl)).
[9.3,10.3] 
The second step is the dehydration of the carboxamide group, leading the 
corresponding nitrile. This transformation may be delayed to a later stage, 
keeping the prolinamide residue through the following step.[14.3] In the prior 
art trifluoroacetic anhydride,[8.3,11.3,13.3,15.3] 2,4,6-trichloro-1,3,5-triazine 
(cyanuric chloride),[11.3] Vilsmeier’s reagent[9.3,16.3] or phosphoryl chloride[13.3] 
were used as dehydrating agents. 
The obtained haloacetyl-derivative is then used as alkylating agent for the 
reaction with 3-amino-1-adamantanol 5.3. Compound 5.3 is commercially 
available or can be prepared by direct oxidation of 1-aminoadamantane 
(HNO3/H2SO4).
[12.3,15.3] 
The N-alkylation of the compound 5.3 is generally performed by using 
K2CO3 as base.
[8.3] Nevertheless, this reaction is often plagued by the 
unwanted formation of the bis-alkylated byproduct 6.3, which is very difficult 
to remove from vildagliptin 1.3 and determines a drop of the overall process 
yield (Scheme 2.3).[12.3] This bis-alkylated byproduct may be formed even if 
3-amino-1-adamantanol 5.3 is alkylated in the early steps.[12.3] Reductive 
amination with glyoxylic acid is reported and this approach can partially 
circumvent the problem of the bis-alkylation.[17.3] 
 
Scheme 2.3 - Formation of the bis-alkylation byproduct 
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N
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 22 
 
Problems related to the previous synthetic strategies led us to study a new 
route for the preparation of vildagliptin, to avoid these issues and to prevent 
the formation of byproducts. Our alternative synthesis starts from the 
observation that glyoxylic acid is known to react with primary amines in a 
one-pot formylation and carboxymethylation of the nitrogen atom.[18.3] This 
represent the best way for the simultaneous introduction of the C2-linker 
moiety on the amino group of the 3-amino-1-adamantanol 5.3, leading to a 
key intermediate 7.3 avoiding the formation of the bis-alkylated compound 
(Scheme 3.3). 
 
Scheme 3.3 - new approach to vildagliptin 
With this key intermediate we developed a novel and original 4-step 
synthesis for the preparation of vildagliptin (Scheme 4.3).[19.3, 20.3] 
Initially, the key intermediate 7.3 was generated by reacting 3-amino-1-
adamantanol 5.3 with 3 equivalents of glyoxylic acid (50%w/w aq. solution) at 
70°C for 4 hours, performing the one-pot N-formylation/N-
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carboxymethylation. At the end of the reaction, the obtained mixture was 
slowly cooled at room temperature and the product was collected by simple 
filtration in good yield (86%). 
To complete the assembly of the entire backbone of the final product, the 
key intermediate 7.3 was directly reacted, in the second step of this 
synthesis, with the selected raw material L-prolinamide in a dehydrative 
coupling. Initially the carboxylic function of 7.3 was activated by using N,N’-
carbonyldiimidazole as condensing agent and tetrahydrofuran as solvent. 
Subsequently, the desired amide 8.3 was obtained by adding L-prolinamide 
and maintaining the mixture at 40°C for 15 hours. Since the purification of 
compound 8.3 was complex, due to its high water-solubility, it was used 
directly in the next step without purification.  
 
Scheme 4.3 - new route of synthesis of vildagliptin 
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By using the combination ethyl nicotinate/trifluoroacetic anhydride[21.3], the 
primary amide of intermediate 8.3 (tetrahydrofuran solution) was 
transformed in the corresponding nitrile (room temperature, 1 hour, 91% 
yield). During the reaction, the hydroxyl group of the adamantane moiety 
was also protected as the corresponding trifluoroacetyl to give the 
compound 9.3, isolated after a simple work-up.  
The last step of the reported synthesis consisted in a cleavage of the 
protecting groups (O-trifluoroacetyl and N-formyl), leading the final API 
vildagliptin 1.3. The product was achieved by reacting 9.3 with aqueous 
trifluoroacetic acid (5.4%w/w) at 86°C for 15 hours, followed by the 
crystallization of the crude product from 2-butanone. Highly pure (>99.5%) 
vildagliptin 1.3 was obtained in a 81% yield as a white crystalline 
powder.[19.3, 20.3] 
 
3.4 Conclusion and future developments 
We report an innovative and convenient synthetic approach for the 
preparation of the important DPP-IV inhibitor vildagliptin 1.3. This 4-step 
synthesis, consisting in a one-pot N-formylation-N-carboxymethylation of 
the amino group of the commercially available adamantane derivative 5.3, 
leading to vildagliptin in a 63% overall yield. Previously reported syntheses 
ranged from 18%[15.3] to 55%[12.3] overall yield, worse than the way reported 
in this work. Moreover, the final product and all intermediate do not require 
chromatographic separation during the work-up, allowing the entire protocol 
to be adapted and performed on a large scale and easily transferable to the 
industrial production. In addition to this work, a patent[20.3] was filed by 
Chemelectiva s.r.l., claiming the key intermediates 7.3, 8.3 and 9.3. 
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3.5 Experimental section 
3.5.1 Materials and methods 
The chemicals used for the experiments were of the highest analytical 
grade. Nuclear magnetic resonance spectra (1H, 13C-NMR) were recorded 
on a JEOL ECP300 (7.04 T) spectrometer. Chemical shifts (δ) are quoted 
in parts per million (ppm) and referenced to the residual solvent peak. 
Coupling constants (J) are quoted in Hertz (Hz). Mass spectra (MS) were 
recorded on a ThermoFinnigan TSQ700 triple-quadrupole instrument 
equipped with an electrospray ionization source. DSC analysis were 
performed on a Nietzsch DSC 3500 Sirius instrument; the sample (~2 mg) 
was placed in an aluminum pierced pan and heated from 35°C to 400°C 
(heating rate 10°C/min) in a dry nitrogen atmosphere. 
3.5.2 Synthesis of N-formyl-N-(3-hydroxy-1-adamantyl)aminoacetic 
acid (7.3) 
3-Amino-1-adamantanol (5.3, 50.00 g, 0.299 mol) was suspended in ethyl 
acetate (350 mL) at room temperature. Formic acid 95% (15.80 mL, 0.419 
mol) was added dropwise in about 10 minutes (slightly exothermic 
reaction). Aqueous glyoxylic acid (50%w/w, 79.15 mL, 0.717 mol) was added 
and the suspension was heated at 70°C and stirred for 6 hours (formation 
of CO2 was observed). After this period the reaction was cooled to room 
temperature in about 30 minutes and maintained at this temperature for 
further 30 minutes allow the complete precipitation of the product. The 
suspension was filtered and the solid was washed twice with acetone/water 
2:1 (50 mL). The solid was dried in a vacuum oven at 45±5°C until constant 
weight to give N-formyl-N-(3-hydroxy-1-adamantyl)aminoacetic acid (7.3, 
65.40 g, 86% yield) as a yellowish solid. 
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1H-NMR (300 MHz, D2O): δ (ppm) = 8.52 (s, 1H), 4.29 (s, 2H), 2.48 (m, 
2H), 2.00 (m, 6H), 1.86 (m, 4H), 1.69 (m, 2H). 
13C-NMR (75.6 MHz, D2O): δ (ppm) = 173.24 (C), 162.68 (CH), 69.83 (C), 
59.88 (C), 47.54 (CH2), 42.46 (CH2), 42.13 (CH2), 39.39 (CH2), 33.83 (CH2), 
30.36 (CH). 
MP = 218.6°C (DSC). 
ESI-MS m/z 254.2 [M+H]+ (calcd for C13H19NO4, 253.1). 
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3.5.3 Synthesis of 1-[N-formyl-N-(3-trifluoracetyloxy-1-
adamantyl)aminoacetyl]pyrrolidine-2-carbonitrile (9.3) 
N,N’-Carbonyldiimidazole (121.20 g, 0.747 mol) was suspended in 
tetrahydrofuran (1030 mL) then the suspension was heated to 30±5°C to 
obtain complete dissolution. The reaction was cooled to room temperature 
and N-formyl-N-(3-hydroxy-1-adamantyl)aminoacetic acid (7.3, 159.00 g, 
0.628 mol) was added in 4 portions in about 30 minutes. The resulting 
suspension was stirred at room temperature until complete dissolution (~1 
hour). During this time the evolution of CO2 was observed. L-Prolinamide 
(76.66 g, 0.672 mol) was then added and the reaction mixture was stirred 
and heated to 40±2°C for 15 hours. Complete solution was observed 
followed by incipient precipitation of 1-[N-formyl-N-(3-hydroxy-1-
adamantyl)aminoacetyl]pyrrolidine-2-carboxamide (8.3). The suspension 
was cooled to room temperature. In a separate flask ethyl nicotinate 
(332.25 g, 2.198 mol) was dissolved in tetrahydrofuran (890 mL) and the 
reaction was cooled to 0±5°C. Trifluoroacetic anhydride (461.91 g, 2.198 
mol) was added dropwise in about 30 minutes. The resulting solution was 
added dropwise to the stirred suspension of 8.3 in about 30 minutes, 
maintaining the temperature at 25±3°C. The reaction mixture then was 
stirred at room temperature for 1 hour. The solvent was removed under 
reduced pressure. Toluene (1900 mL) and water (750 mL), cooled at 10°C, 
was added to the oily residue. The addition of water is slightly exothermic. 
The mixture was stirred until complete dissolution of the oily residue. The 
two phases were separated, and the organic layer was washed with 1N 
aqueous HCl (1x850 mL), water (3x850 mL) and saturated aqueous NaCl 
(1x750 mL). The organic phase was filtered on a Celite®/charcoal pad and 
the filter was washed with toluene (150 mL). The solvent was removed 
under reduced pressure to obtain 1-[N-formyl-N-(3-trifluoracetyloxy-1-
adamantyl)aminoacetyl]pyrrolidine-2-carbonitrile (9.3, 244.61 g, 91% yield) 
as a yellow oily product, directly used in the following step. 
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1H-NMR (300 MHz, CDCl3, mixture of rotamers in approx. ratio 80:20): δ 
(ppm, major rotamer) = 8.48 (s, 1H), 4.76 (dd, 1H, J1 = 6.8 Hz, J2 = 2.3 Hz), 
4.21 (d, 1H, J = 16.3 Hz), 3.84 (d, 1H, J = 16.2 Hz), 3.65 (m, 2H), 2.47-1.90 
(m, 16H), 1.65 (d, 1H, J = 14.2 Hz), 1.63 (d, 1H, J = 14.4 Hz). δ (ppm, 
minor rotamer) = 8.47 (s, 1H), 4.98 (dd, 1H, J1 = 7.1 Hz, J2 = 3.1 Hz), 4.32 
(d, 1H, J = 15.9 Hz), 3.91 (d, 1H, J = 15.9 Hz), 3.54 (m, 2H), 2.47-1.59 (m, 
18H). 
13C-NMR (75.6 MHz, CDCl3, mixture of rotamers in approx. ratio 80:20): δ 
(ppm, major rotamer) = 167.0 (C), 161.4 (CH), 155.9 q(C) JC-F = 41.6 Hz, 
118.4 (C), 114.3 q(C) JC-F = 287.1 Hz, 85.9 (C), 58.5 (C), 46.8 (CH), 46.1 
(CH2), 45.4 (CH2), 42.3 (CH2), 40.7 (CH2), 39.3 (CH2), 34.2 (CH2), 30.6 
(CH), 29.9 (CH2), 25.4 (CH2). δ (ppm, minor rotamer, selected signals) = 
167.2 (C), 161.6 (CH), 155.9 q(C) JC-F = 41.8 Hz, 118.8 (C), 85.8 (C), 58.7 
(C), 47.1 (CH), 46.8 (CH2), 45.6 (CH2), 42.7 (CH2), 40.8 (CH2), 39.4 (CH2), 
32.5 (CH2), 30.6 (CH), 23.1 (CH2). 
ESI-MS m/z 428.3 [M+H]+ (calcd for C20H24F3N3O4, 427.2). 
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3.5.4 Synthesis of vildagliptin (1.3) 
1-[N-formyl-N-(3-trifluoracetyloxy-1-adamantyl)aminoacetyl]pyrrolidine-2-
carbonitrile (9.3, 244.61 g, 0.572 mol) was suspended in water (680 mL). 
The oily suspension was vigorously stirred and trifluoroacetic acid (39.15 g, 
0.343 mol) was added, then the reaction mixture was heated at 86±2°C for 
15 hours. The clear solution was cooled to room temperature and NaCl 
(250.00 g) was added. Stirring was maintained until complete dissolution of 
the inorganic salt. Aqueous NaOH (30%w/w, 147.80 mL) was added 
dropwise in about 15 minutes. Dichloromethane (670 mL) was added and 
the reaction mixture was stirred for 30 minutes. The organic phase was 
separated, and the aqueous layer was washed twice with dichloromethane 
(180 mL). The organic extract and washings were combined and washed 
with a solution of NaCl (60.00 g), NaHCO3 (6.10 g) and water (300 mL). 
The solvent was removed under reduced pressure to obtain the crude 1.3. 
2-Butanone (500 mL) was added and the suspension was heated at reflux 
until complete dissolution. The solution was filtered hot through a 
Celite®/charcoal pad and the filter was washed with 2-butanone (60 mL, 
60°C). The solution was cooled to 20±2°C, under stirring, in about 2 hours. 
Crystallization of the product was observed, and the suspension was 
maintained under stirring for about 2 hours to complete the precipitation 
process. The suspension was filtered and the solid was washed twice with 
2-butanone (60 mL). The purified wet product was dried in a vacuum oven 
at 45°C to give vildagliptin (1.3, 140.6 g, 81% yield) as a colorless solid. 
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1H-NMR (300 MHz, CDCl3): δ (ppm) = 4.85 (dd, 0.2H, J1 = 7.6 Hz, J2 = 2.0 
Hz), 4.74 (m, 0.8H), 3.68-3.34 (m, 0.8H+3.2H), 2.35-1.80 (1.6H+6.4H), 
1.68-1.42 (m, 2.4H+9.6H). 
13C-NMR (75.6 MHz, CDCl3): δ (ppm) = 170.64 (C), 118.33 (C), 69.64 (C), 
53.64 (C), 49.93 (CH2), 46.64 (CH), 45.58 (CH2), 44.46 (2xCH2), 43.49 
(CH2), 41.37 (CH2), 41.20 (CH2), 35.21 (CH2), 30.78 (CH), 30.00 (CH2), 
25.15 (CH2). 
MP = 153.3°C (DSC). 
ESI-MS m/z 304.3 [M+H]+ (calcd for C17H25N3O2, 303.2). 
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4. Fexofenadine 
The API fexofenadine 1.4 (Figure 1.4) is a second-generation oral H1-
antihistamine, used worldwide for the treatment of allergic rhinitis (AR). It 
was selected as the target of the second year of the PhD, with the aim to 
achieve the same goals as the first year (R&D of a new route of synthesis 
and the corresponding scale up). 
 
Figure 1.4 - Fexofenadine 
 
4.1 Allergic rhinitis 
Allergic rhinitis (AR) is a common inflammatory disease of the nose, 
induced by allergen exposure, which includes pollens, animal danders, 
airborne dust mite fecal particles and molds.[1.4] 
AR affects 10% to 25% of people worldwide and up to 40% of the 
population of some countries (about 31 million people annually in the 
United States).[1.4,2.4] This pathology is characterized by 4 main symptoms 
like rhinorrea, sneezing, itching and nasal congestion. The latter is the 
predominant manifestation of AR and has a severe impact on the 
quality/duration of sleep, quality of life, ability to perform daily activities and 
school/work performances.[2.4] Nasal congestion is associated with sleep-
disordered breathing, a condition that can have important effects on mental 
health, including psychiatric disorders.[3.4] 
Inhalation of pollen allergens and their subsequent contact with the 
epithelial layer of the respiratory tract (upper airway and, possibly, lower 
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airway mucosa) causes an interaction with antigen presenting cells, in 
particular with histocompatibility complex molecules. This interaction 
triggers a development of specific classes of TH2-cells, followed by the 
production of allergen-specific IgE (Figure 2.4). The IgE response mediates 
degranulation of basophils and mast-cells which release different 
substances (e.g. histamine, leukotrienes, tryptase) playing the role of 
mediators of AR symptoms.[3.4,4.4] 
 
Figure 2.4 - Pathophysiology of allergic rhinitis
[4.4] 
 
4.2 Oral antihistamines for the AR treatment 
Histamine is the major mediator of the early-phase reaction, stimulating 
sensory nerves and causing the AR symptoms, by interaction with its 
receptor H1. This receptor mediate an increased vascular and epithelial 
permeability in the nasal mucosa, with the consequent vasodilatation and 
plasma extravasion.[2.4,4.4] 
With the aim to block this cascade of events, a class of oral H1-
antihistamines was developed (Figure 3.4). These molecules, which are not 
structurally similar to histamine, are not receptor antagonists but bind H1-
receptor in different sites, to produce the opposite effect (inverse 
agonist).[5.4] 
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Figure 3.4 - H1-Antihistamines 
There are two classes of oral H1-antihistamines (Figure 3.4): 
- 1st generation antihistamines (e.g. chlorphenamine, 
diphenhydramine, promethazine); 
- 2nd generation antihistamines (e.g. cetirizine, fexofenadine). 
The formers are no longer the treatment of choice for allergic rhinitis 
because of their adverse-effect profile, including poor selectivity 
(anticholinergic effects), cardiovascular effects, somnolence and sedation. 
Second generation H1-antihistamines have become the preferred therapy 
for AR because their minimal or reduced sedative effects, high potency, 
longer duration of action compared with 1st generation drugs and 
pharmacodynamic properties that allow once-daily dosing.[2.4,3.4] 
Fexofenadine hydrochloride is a potent, non-sedating and selective H1-
antihistamine and has a favourable effect on nasal congestion. Results of 
comparative trials showed that fexofenadine hydrochloride might offer many 
advantages compared with some others H1-antihistamines. It is also 
selective for peripheral H1-receptors and does not cross the blood-brain 
barrier. In addition fexofenadine hydrochloride is well tolerated in children 
aged 2-5 years with allergic rhinitis.[3.4] 
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4.3 Results and discussion 
The API fexofenadine hydrochloride 1.4 (Scheme 1.4) includes an aromatic 
ring (-dimethylphenylacetic acid) bearing in para position a C4-aliphatic 
linker, terminating with azacyclonol (2.4, -diphenyl-4-
piperidinemethanol). The carbon atom directly connected to the aromatic 
moiety carries a secondary alcohol. This stereocenter configuration is 
racemic in the commercial product. 
 
Scheme 1.4 - Retrosynthetic approaches to fexofenadine hydrochloride 
Retrosynthetic approaches for the preparation of fexofenadine 
hydrochloride 1.4 rely on a common disconnection of the azacyclonol 2.4 
(commercially available and cheap). The latter was introduced as such by a 
standard SN2 nucleophilic displacement exploiting the presence of a leaving 
group (= LG) on the other precursor. 
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The alkylating agents used in this cross-coupling are intermediates 3.4 and 
4.4, consisting of the aralkyl portion and bearing a terminal leaving group, 
reactive in the SN2 with azacyclonol 2.4. Both the intermediates contain a 
group playing the role of precursor of the final secondary alcohol (keto 
group and alkyne moiety, respectively for intermediates 3.4 and 4.4). 
Classical leaving groups employed in the alkylation step are represented by 
sulfonate esters (LG = OMs[6]) and all halogen atoms (LG = Cl,[7] Br, I[8]). 
The C≡C triple bond may be formally hydrated to convert 4.4 to 
intermediate 3.4, or later after the alkylation of azacyclonol. 
The key intermediates 3.4 and 4.4 share the common precursor 5.4, 
represented by -dimethylphenylacetic acid (R = COOH), precursors 
such as the corresponding nitrile (R = CN[9]), primary alcohol (R = 
CH2OH
[7]), the oxazoline[8] (converted to the carboxylic function during the 
multistep route of synthesis) and derivatives as the esters (R = COOMe, 
COOEt). 
The -LG-butanoyl side chain of the compound 3.4 may be directly 
introduced with a Friedel-Crafts acylation of 4-chlorobutanoyl halides on 
intermediate 5.4.[10] An alternative strategy consists in the introduction of a 
cyclopropanecarbonyl residue as a synthetic equivalent (compound 6.4),[11] 
whose strained 3-membered rings could be easily opened to the linear-
chain counterpart.[7] In a different approach, the alkynyl side chain of 
intermediate 4.4 is almost exclusively linked to the aromatic ring by a 
Sonogashira coupling[6] on the cheap and commercially available -
dimethylphenylacetic acid or esters thereof (7.4). 
All the starting materials, used in these approaches, are commercially 
available at low price and most of the reactions are easy and practical. For 
these reasons our synthetic approach started from methyl 2-(4-
bromophenyl)-2-methylpropanoate and take advantage on its proclivity to 
react efficiently with alkynes in the Sonogashira coupling.[12] 
Nevertheless, the hydration of the C≡C triple bond of the intermediate 
arising from the Sonogashira reaction requires harsh conditions and toxic 
reagent, hardly compatible with large scale production. In a first example 
(Scheme 2.4), HgO in aqueous H2SO4 was used for the transformation of 
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the alkyne moiety in a keto group,[6] while in another patent the use of 
copper tetrafluoborate in refluxing aqueous methanol was described. [8] 
Another big problem for the industrial application of these hydration of the 
C≡C triple bond is the generation of toxic reaction wastes, difficult to 
dispose. 
 
Scheme 2.4 - Existing protocols for the C≡C triple bond hydration 
With the aim to eliminate the use of metal ions (either difficult to remove 
and toxic), we started to study new and alternative protocols for the alkyne 
hydration. 
We found that the presence of a hydroxyl group, at the correct distance 
from the triple bond, gave an anchimeric assistance and increase the 
alkynyl group reactivity, for example in a reduction mediated by LiAlH4.
[13,14] 
For these reason we used 3-butyn-1-ol as the alkyne partner in the 
Sonogashira reaction. The hydroxyl group plays the double role of 
intramolecular assistance[15] and may finally converted to a leaving group 
for the subsequent attack of the azacyclonol residue. 
By using appropriate conditions (CuI, PPh3, PdCl2(PPh3)2 as catalyst and 
triethylamine, 70 °C for 7 h) we obtained the desired -hydroxyalkyne 9a.4 
in 98% yield (Scheme 3.4). 
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Scheme 3.4 - Improved synthetic protocol to fexofenadine hydrochloride. No reaction was 
observed for compound 9b.4  
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Treatment of this intermediate with 48%w/w aqueous HBr in refluxing 
methanol, give after 4 hours of reaction a mixture of two products, initially 
separated by a silica gel column cromatography and identified a methyl 2-
(4-(4-methoxybutanoyl)phenyl)-2-methylpropanoate 10.4 and methyl 2-(4-
(4-bromobutanoyl)phenyl)-2-methylpropanoate 11.4 (ratio 10.4/11.4: 
20:80). 
The structure of both these compounds confirms the successful addition to 
the C≡C triple bond. The formation of these two molecules, -
methoxyketone 10.4 and -bromoketones 11.4, suggests the important 
anchimeric assistance of the remote hydroxyl group. A mechanistic 
hypothesis (Scheme 4.4) suggests that the formation of the -substituted 
ketones 10.4 and 11.4 arise from a 5-endo-dig cyclization (intramolecular 
attack of the OH-group to the triple bond), allowed according to the original 
Baldwin rules.[17] After the initial formation of a protonated 2-aryl-4,5-
dihydrofurane in prototropic equilibrium with the isomeric 5-aryl-3,4-dihydro-
2H-furan-1-ium ion, the latter undergoes nucleophilic attack (ring-opening) 
either by the bromide anion to give compound 11.4, or of methanol leading 
to the generation of the -methoxyketone 10.4 as a by-product. 
 
Scheme 4.4 - Proposed mechanism 
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To gain additional information about this unexpected cyclisation process, 
we synthesised the -hydroxyalkyne 9b.4. This lower homologue of 9a.4 
was also prepared via Sonogashira coupling in a 93% yield, by using 2-
propyn-1-ol. Intermediate 9b.4 was treated in the same conditions (reaction 
9a.4 → 10.4+11.4). No conversion was observed even after prolonged 
reaction times (Scheme 3.4), with quantitative recovery of the starting 
material unchanged. 
Even if the transformation of 9b.4 involves a formally allowed 4-endo-dig 
cyclization, according to Baldwin rules, it is likely that the high strain of the 
incoming 4-membered 4-aryl-2H-oxete hinders its formation in the used 
conditions. A new revision of the original Baldwin rules showed the 
generally unfavourable outcome of these cyclization process.[17] This further 
supports that the hydroxyl group must be located in the correct position to 
give assistance and exploit its beneficial role. 
The formation of a mixture of -bromoketone 11.4 and -methoxyketone 
10.4 is not suitable for a future scale-up of the process, so we tried to direct 
the reaction toward a single product. We explored the possibility to convert 
the by-product 10.4 in the desired intermediate 11.4, as reported in 
literature (cleavage of alkyl ethers),[18] by treating the raw mixture with 
33%w/w HBr/AcOH (rt, 4 hours). Gratifyingly, in these conditions, the mixture 
of the two compounds converged to a single product, represented by the -
bromoketone 11.4 in a 93% overall yield on two steps. 
An attempt to perform a one-pot hydration/cleavage of ether (9a.4→11.4) 
was made by refluxing the substrate in 33%w/w HBr/AcOH. This reaction 
gave a complex reaction mixture including 11.4, along with an elevate 
number of unidentified by-products. 
The -bromoketone 11.4 paves the way for the preparation of fexofenadine 
hydrochloride 1.4, representing a key intermediate important for the 
introduction of the azacyclonol residue. However, the ketone group needs 
to be suitably protected, prior to the SN2 reaction with azacyclonol 2.4. This 
protection was exploited with trimethylorthoformate and catalytic sulphuric 
acid in methanol (reflux temperature, 2 hours, 90% yield), leading the O,O-
dimethylacetal 12.4. 
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The -bromoketal reacts cleanly with azacyclonol using, in a biphasic 
mixture of toluene and water, sodium bicarbonate as the base and 
potassium iodide as the catalyst. After 5 hours at reflux temperature the 
advanced intermediate 13.4 was obtained in high yield (88%). 
30%w/w Aqueous NaOH in methanol (4 hours, reflux temperature) was used 
to hydrolyse the ester moiety of the intermediate 13.4, isolated after 
acidification with acetic acid in the corresponding zwitterionic form 14.4 in 
an excellent 97% yield. 
The subsequent step consisted in a conversion of the ketal group in the 
secondary alcohol, representing the correct functional group of 
fexofenadine hydrochloride 1.4 (racemic). Initially, by using 37%w/w 
aqueous HCl, the ketal moiety was hydrolysed to regenerate the ketone 
group. Without further isolation of the keto-acid, addition of NaBH4 
concluded this one-pot hydrolysis/reduction, obtaining fexofenadine base 
15.4 in very high yield (97%). 
By the addition of 37%w/w aqueous HCl to a solution of fexofenadine base 
15.4 in ethyl acetate, the last synthetic step was completed. After a short 
induction time, fexofenadine hydrochloride 1.4 starts to precipitate and was 
collected by filtration after 2 hours. After an additional digestion in acetone, 
analytically pure (> 99.5%) 1 was obtained as a white crystalline powder. 
This 8-steps approach led in to the final API in an overall 59% yield. 
Moreover, the whole described process can be performed on a large scale 
(reported yields are referred to a 100 grams scale) and easily scaled to the 
industrial production,[19] also thanks to the fact that chromatographic 
separation was avoided in the isolation and purification of fexofenadine 
hydrochloride 1.4 and all the intermediates. 
The entire protocol for the preparation of fexofenadine hydrochloride was 
applied for the synthesis of a similar API, terfenadine hydrochloride 23.4. 
The aim of this work was to test the generality of all the steps used in our 
novel synthetic approach, first of all the formal alkyne hydration. 
To this purpose, 1-bromo-4-t-butylbenzene 16.4 (Scheme 5.4) was used as 
the starting material. By using a Sonogashira reaction, with the same 
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conditions reported for fexofenadine, the -hydroxyalkyne 17.4 was 
obtained in 94% yield.  
 
Scheme 5.4 - Adapted route of synthesis for terfenadine hydrochloride 
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As expected, the treatment of the latter with 48%w/w aqueous HBr in 
methanol at reflux temperature for 4 hours gave a mixture of two 
compounds identified as the -bromoketone 19.4 and the -methoxyketone 
18.4. Application of the same strategy for the raw mixture of 10.4/11.4, 
allowed a total conversion of 18.4+19.4 into 19.4 (33%w/w HBr/AcOH, 91% 
yield of the -bromoketone). 
Protection of the carbonyl group was achieved by reaction with 
trimethylorthoformate and catalytic sulphuric acid in methanol. After 2 hours 
at reflux temperature, the corresponding -bromoketal 20.4 was isolated in 
high yield (88%). This protection was followed by the alkylation of the 
nitrogen atom of the azacyclonol 2.4 (NaHCO3, KI as catalyst, biphasic 
mixture of water/toluene, 5 h, 90% yield). Hydrolysis of the ketal group of 
the obtained product 21.4, led to the aminoketone 22.4, converted in the 
last step of this synthesis into terfenadine hydrochloride 23.4, according to 
an existing protocol known in literature.[12] This preparation was 
characterised by a 50% overall yield (7 steps). 
 
4.4 Conclusion and future developments 
In this work we reported an innovative and scalable synthetic strategy for 
the preparation of fexofenadine hydrochloride 1.4, an important H1-
antihistamine. The synthesis consists in 8 steps, relying on a intramolecular 
cyclization which allows to perform a facile hydration of the C≡C triple bond. 
This approach led to fexofenadine hydrochloride 1.4 in a good overall yield 
(59%) and can be adapted for the preparation of similar molecules, e.g. 
terfenadine hydrochloride 23.4 (50% overall yield). No chromatographic 
separations are required, during work up, to isolate intermediates and final 
product, allowing the process to be performed on an industrial scale. 
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4.5 Experimental section 
4.5.1 Materials and methods 
The chemicals used for the experiments were of the highest analytical 
grade. Nuclear magnetic resonance spectra (1H, 13C-NMR) were recorded 
on a JEOL ECP300 (7.04 T) spectrometer. Chemical shifts (δ) are quoted 
in parts per million (ppm) and referenced to the residual solvent peak. 
Coupling constants (J) are quoted in Hertz (Hz). Mass spectra (MS) were 
recorded on a ThermoFinnigan TSQ700 triple-quadrupole instrument 
equipped with an electrospray ionization source. DSC analysis were 
performed on a Nietzsch DSC 3500 Sirius instrument; the sample (~2 mg) 
was placed in an aluminum pierced pan and heated from 35°C to 400°C 
(heating rate 10°C/min) in a dry nitrogen atmosphere. 
 
4.5.2 Synthesis of methyl 2-(4-(4-hydroxybut-1-ynyl)phenyl)-2-
methylpropanoate (9a.4) 
A solution of methyl 2-(4-bromophenyl)-2-methylpropanoate (8.4, 0.416 
mol, 107.0 g) in triethylamine (1.040 mol, 144.2 mL) was stirred under 
nitrogen flux for 15 minutes. Triphenylphosphine (0.003 mol, 0.66 g) and 
CuI (0.002 mol, 0.31 g) was added and the reaction mixture was stirred 
until complete dissolution was obtained. To the resulting solution 
dichlorobis(triphenylphosphine)palladium(II) (0.001 mol, 0.58 g) was added 
and the reaction was heated to 70°C. 3-Butyn-1-ol (0.458 mol, 34.5 mL) 
was added dropwise over a period of 4 hours. At the end of the addition the 
resulting reaction mixture was stirred at 70°C for 7 hours. The reaction 
mixture was allowed to warm to room temperature and toluene (300 mL) 
was added. Aqueous HCl (3.5M, 180 mL) was added dropwise, maintaining 
the temperature under 30°C (slightly exothermic). At the end of the addition 
the phases were separated, and the organic layer was washed with water 
(3x150 mL). Charcoal (5 g) was added and the mixture was stirred for 30 
minutes then was filtered off on a Celite® pad. The filter was washed with 
toluene (2x20 mL) and the solvent was removed under reduced pressure to 
give methyl 2-(4-(4-hydroxybut-1-ynyl)phenyl)-2-methylpropanoate (9a.4, 
100.0 g, 98% yield) as an orange oil. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.35 (2H, d, J = 8.3 Hz), 7.27 
(2H, d, J = 8.6 Hz), 4.88 (1H, t, J = 5.5 Hz), 3.59 (5H, m), 2.55 (2H, t, J = 
6.9 Hz), 1.48 (6H, s). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 176.0 (C), 144.3 (C), 131.3 
(CH), 125.7 (CH), 121.6 (C), 88.5 (C), 80.7 (C), 59.8 (CH2), 52.1 (CH3), 
46.1 (C), 26.1 (CH3), 23.3 (CH2). 
FT-IR (KBr): ṽ = 3413, 2978, 2950, 2885, 1729, 1508, 1467, 1435, 1255, 
1147, 1098, 1046, 838 cm-1. 
ESI-MS m/z 247.1 [M+H]+ (calcd for C15H18O3, 246.1). 
 
 
 
 
 
 
 
 
 
COOMe
HO
9a.4
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4.5.3 Synthesis of methyl 2-(4-(3-hydroxyprop-1-ynyl)phenyl)-2-
methylpropanoate (9b.4) 
A solution of methyl 2-(4-bromophenyl)-2-methylpropanoate (8.4, 0.019 
mol, 5.0 g) in triethylamine (0.049 mol, 6.7 mL) was stirred under nitrogen 
flux for 15 minutes. Triphenylphosphine (0.12 mmol, 31 mg) and CuI (0.10 
mmol, 19 mg) was added and the reaction mixture was stirred until 
complete dissolution was obtained. To the resulting solution 
dichlorobis(triphenylphosphine)palladium(II) (0.04 mmol, 27 mg) was added 
and the reaction was heated to 70°C. 2-Propyn-1-ol (0.021 mol, 1.3 mL) 
was added dropwise over a period of 4 hours. At the end of the addition the 
resulting reaction mixture was stirred at 70°C for 7 hours. The reaction 
mixture was allowed to warm to room temperature and toluene (15 mL) was 
added. Aqueous HCl (3.5M, 9 mL) was added dropwise, maintaining the 
temperature under 30°C (slightly exothermic). At the end of the addition the 
phases were separated, and the organic layer was washed with water (3x9 
mL). Charcoal (0.25 g) was added and the mixture was stirred for 30 
minutes then was filtered off on a Celite® pad. The filter was washed with 
toluene (2x1 mL) and the solvent was removed under reduced pressure to 
give methyl 2-(4-(3-hydroxyprop-1-ynyl)phenyl)-2-methylpropanoate (9b.4, 
4.2 g, 93% yield) as an orange oil. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.39 (d, 2H, J = 8.6 Hz), 7.30 (d, 
2H, J = 8.3 Hz), 5.35 (t, 1H, J = 6.0 Hz), 4.32 (d, 2H, J = 5.5 Hz), 3.58 (s, 
3H), 1.49 (s, 6H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 176.1 (C), 144.9 (C), 131.3 
(CH), 125.9 (CH), 120.9 (C), 89.9 (C), 83.3 (C), 52.1 (CH3), 49.6 (CH2), 
46.2 (C), 26.1 (CH3). 
FT-IR (KBr): ṽ = 3432, 2978, 2943, 2870, 1729, 1507, 1467, 1435, 1256, 
1148, 1098, 1024, 838 cm-1. 
ESI-MS m/z 233.2 [M+H]+ (calcd for C15H18O3, 232.1). 
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4.5.4 Synthesis of methyl 2-(4-(4-bromobutanoyl)phenyl)-2-
methylpropanoate (11.4) 
A solution of 2-(4-(4-hydroxybut-1-ynyl)phenyl)-2-methylpropanoate (9a.4, 
0.406 mol, 100.0 g) in methanol (200 mL) was cooled down to 10°C and 
aqueous HBr (48%w/w, 0.406 mol, 45.9 mL) was added dropwise, 
maintaining the temperature below 25°C. At the end of the addition, the 
reaction mixture was heated to reflux temperature for 4 hours. The solution 
was then cooled down to room temperature and the solvent was removed 
under reduced pressure to give a mixture of methyl 2-(4-(4-
methoxybutanoyl)phenyl)-2-methylpropanoate 10.4 and methyl 2-(4-(4-
bromobutanoyl)phenyl)-2-methylpropanoate 11.4 as a brown oil. A small 
aliquot of the mixture was subjected to column chromatography (eluant 
hexane-ethyl acetate 95:5), obtaining an analytical sample of 10.4. The 
whole residue was cooled down to 5°C and acetic HBr (33%w/w, 100 mL) 
was added dropwise, maintaining the temperature below 20°C. At the end 
of the addition the resulting mixture was stirred at room temperature for 4 
hours. At the end of the reaction toluene (250 mL) and water (100 mL) were 
added. The phases were separated and the product was extracted with 
toluene (30 mL). The combined organic phases were washed with aqueous 
NaHCO3 saturated solution (150 mL) and the solvent was removed under 
reduced pressure to give methyl 2-(4-(4-bromobutanoyl)phenyl)-2-
methylpropanoate (11.4, 123.0 g, 93% yield) as a brown oil. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.93 (d, 2H, J = 8.3 Hz), 7.44 (d, 
2H, J = 8.3 Hz), 3.60 (s, 3H), 3.36 (t, 2H, J = 6.3 Hz), 3.22 (s, 3H), 3.03 (t, 
2H, J = 7.2 Hz), 1.85 (quint, 2H, J = 6.7 Hz), 1.52 (s, 6H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 199.0 (C), 175.8 (C), 149.6 (C), 
135.1 (C), 128.0 (CH), 125.9 (CH), 71.1 (CH2), 57.7 (CH3), 52.1 (CH3), 46.4 
(C), 34.6 (CH2), 26.1 (CH3), 23.8 (CH2). 
FT-IR (KBr): ṽ = 2978, 2931, 2877, 1731, 1683, 1606, 1464, 1407, 1367, 
1256, 1148, 1097, 992, 845 cm-1. 
ESI-MS m/z 279.3 [M+H]+ (calcd for C16H22O4, 278.2). 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.94 (d, 2H, J = 8.3 Hz), 7.46 (d, 
2H, J = 8.3 Hz), 3.60 (m, 5H), 3.17 (t, 2H, J = 7.0 Hz), 2.17 (quint, 2H, J = 
6.7 Hz), 1.53 (s, 6H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 198.1 (C), 175.7 (C), 149.7 (C), 
134.9 (C), 128.0 (CH), 125.9 (CH), 52.1 (CH3), 46.4 (C), 36.3 (CH2), 34.3 
(CH2), 27.0 (CH2), 26.0 (CH3). 
ESI-MS m/z 327.2/329.2 [M+H]+ (calcd for C15H19BrO3, 326.1/328.1). 
COOMe
O
MeO
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COOMe
O
Br
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4.5.5 Synthesis of methyl 2-(4-(4-bromo-1,1-dimethoxybutyl)phenyl)-2-
methylpropanoate (12.4) 
To a solution of methyl 2-(4-(4-bromobutanoyl)phenyl)-2-methylpropanoate 
(11.4, 0.376 mol, 123.0 g) in methanol (123 mL) were added sulfuric acid 
(0.038 mol, 2.0 mL) and trimethylorthoformate (0.451 mol, 49.4 mL). The 
resulting solution was heated to reflux temperature for 2 hours. At the end 
of the reaction, the solution was cooled down to 20°C and methanolic 
NaOMe (30%w/w, 7.0 mL) was added. The solvent was evaporated under 
reduced pressure and toluene (250 mL) and water (100 mL) were added. 
The phases were separated and the solvent was removed under reduced 
pressure to give methyl 2-(4-(4-bromo-1,1-dimethoxybutyl)phenyl)-2-
methylpropanoate (12.4, 125.8 g, 90% yield) as a brown oil. 
 
 
  
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.36 (d, 2H, J = 8.0 Hz), 7.32 (d, 
2H, J = 8.6 Hz), 3.59 (s, 3H), 3.36 (t, 2H, J = 7.4 Hz), 3.05 (s, 6H), 1.97 (m, 
2H), 1.51 (s, 6H), 1.41 (m, 2H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 176.1 (C), 143.9 (C), 138.6 (C), 
126.6 (CH), 125.1 (CH), 102.5 (C), 51.9 (CH3), 48.0 (CH3), 45.9 (C), 35.1 
(CH2), 34.5 (CH2), 26.9 (CH2), 26.3 (CH3). 
ESI-MS m/z 373.2/375.2 [M+H]+ (calcd for C17H25BrO4, 372.1/374.1). 
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4.5.6 Synthesis of methyl 2-(4-(4-(hydroxydiphenylmethyl)pyperidyn-1-
yl)-1,1-dimethoxybutyl)-phenyl)-2-methylpropanoate (13.4) 
To a solution of NaHCO3 (0.472 mol, 39.7 g) and KI (0.034 mol, 5.6 g) in 
water (250 mL) azacyclonol (0.337 mol, 90.1 g) was added. A solution of 
methyl 2-(4-(4-bromo-1,1-dimethoxybutyl)phenyl)-2-methylpropanoate 
(12.4, 0.337 mol, 125.8 g) in toluene (500 mL) was added and the resulting 
reaction mixture was heated to reflux for 5 hours. At the end of the reaction, 
the mixture was allowed to warm to room temperature and the phases were 
separated. The organic layer was washed with water (250 mL) and the 
organic solvent was removed under reduced pressure to give 2-(4-(4-
(hydroxydiphenylmethyl)pyperidyn-1-yl)-1,1-dimethoxybutyl)phenyl)-2-
methylpropanoate (13.4, 165.6 g, 88% yield) as a brownish oil. 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.49 (d, 4H, J = 7.4 Hz), 7.36 (d, 
2H, J = 8.6 Hz), 7.30 (m, 6H), 7.11 (t, 2H, J = 7.3 Hz), 4.92 (s, 1H), 3.57 (s, 
3H), 3.07 (s, 6H), 2.61 (bd, 2H, J = 11.0 Hz), 2.36 (tt, 1H, J1 = 11.6 Hz, J2 = 
3.1 Hz), 2.05 (bt, 2H, J = 7.0 Hz), 1.87 (m, 2H), 1.75 (bt, 2H, J = 10.7 Hz), 
1.51 (s, 6H), 1.43 (qd, 2H, J1 = 12.2 Hz, J2 = 2.7 Hz), 1.23 (m, 2H), 1.06 
(quint, 2H, J = 7.5 Hz). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 176.2 (C), 147.3 (C), 143.7 (C), 
139.1 (C), 127.7 (CH), 126.7 (CH), 125.7 (CH), 125.0 (CH), 103.1 (C), 78.5 
(C), 57.5 (CH2), 53.6 (CH2), 51.9 (CH3), 48.1 (CH3), 45.9 (C), 43.8 (CH), 
34.2 (CH2), 26.4 (CH3), 26.0 (CH2), 20.6 (CH2). 
FT-IR (KBr): ṽ = 3528, 2952, 2931, 2810, 2771, 1956, 1889, 1748, 1490, 
1448, 1261, 1150, 752, 707 cm-1. 
ESI-MS m/z 560.5 [M+H]+ (calcd for C35H45NO5, 559.3). 
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4.5.7 Synthesis of 2-(4-(4-(hydroxydiphenylmethyl)pyperidyn-1-yl)-1,1-
dimethoxybutyl)phenyl)-2-methylpropanoic acid (14.4) 
To a solution of 2-(4-(4-(hydroxydiphenylmethyl)pyperidyn-1-yl)-1,1-
dimethoxybutyl)phenyl)-2-methylpropanoate (13.4, 0.296 mol, 169.8 g) in 
methanol (450 mL) aqueous NaOH (30%w/w, 0.503 mol, 50.4 mL) was 
added dropwise, maintaining the temperature below 25°C. At the end of the 
addition the reaction mixture was heated to reflux for 4 hours. At the end of 
the reaction, the resulting solution was allowed to warm to room 
temperature and acetic acid (0.503 mol, 28.8 mL) was added dropwise over 
a period of 30 minutes. Precipitation of the product was observed. The 
resulting suspension was stirred at 18°C for 1 hour, in order to maximize 
the precipitation of the product then was filtered, the solid washed with 
methanol/water 2:1 (2x40 mL) and dried in a vacuum oven. The crude was 
suspended in methanol (890 mL) and the resulting suspension was heated 
to reflux. Water (44 mL) was added and the mixture was stirred for 1 hour. 
The suspension was cooled down to 15°C and was stirred for 30 minutes, 
in order to maximize the precipitation of the product. The solid was filtered, 
washed with methanol/water 2:1 (2x40 mL) and dried in a vacuum oven to 
give 2-(4-(4-(hydroxydiphenylmethyl)pyperidyn-1-yl)-1,1-dimethoxybutyl)-
phenyl)-2-methylpropanoic acid (14.4, 148.6 g, 92% yield) as a white solid. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.48 (d, 4H, J = 7.3 Hz), 7.33 (s, 
4H), 7.24 (t, 4H, J = 7.7 Hz), 7.11 (t, 2H, J = 7.3 Hz), 4.27 (bs, >2H, OH + 
NH + moisture), 3.04 (s, 6H), 2.65 (bd, 2H, J = 11.1 Hz), 2.37 (tt, 1H, J1 = 
11.6 Hz, J2 = 3.0 Hz), 2.06 (bt, 2H, J = 7.1 Hz), 1.80 (m, 4H), 1.45 (s, 6H), 
1.40 (m, 2H), 1.20 (bd, 2H, J = 12.5 Hz), 1.04 (quint, 2H, J = 7.8 Hz). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 177.9 (C), 147.2 (C), 145.1 (C), 
138.4 (C), 127.8 (CH), 126.4 (CH), 125.8 (CH), 125.3 (CH), 103.1 (C), 78.5 
(C), 57.1 (CH2), 53.1 (CH2), 48.1 (CH3), 45.8 (C), 43.3 (CH), 34.2 (CH2), 
26.7 (CH3), 25.5 (CH2), 20.2 (CH2). 
MP 191.1°C (DSC). 
FT-IR (KBr): ṽ = 3300-2200 (br), 2956, 2828, 1577, 1471, 1447, 1391, 
1347, 1074, 1041, 746, 706 cm-1. 
ESI-MS m/z 546.3 [M+H]+ (calcd for C34H43NO5, 545.3). 
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4.5.8 Synthesis of fexofenadine (15.4) 
To a suspension of 2-(4-(4-(hydroxydiphenylmethyl)pyperidyn-1-yl)-1,1-
dimethoxybutyl)phenyl)-2-methylpropanoic acid (14.4, 0.272 mol, 148.6 g) 
in methanol (445 mL) aqueous HCl (37%w/w, 0.299 mol, 24.8 mL) was 
added dropwise over a period of 30 minutes. The resulting solution was 
stirred for 1 hour. At the end of the reaction, aqueous NaOH (30%w/w, 0.598 
mol, 60.0 mL) was added dropwise over a period of 30 minutes, 
maintaining the temperature below 30°C (slightly exothermic). At the end of 
the addition, the resulting reaction mixture was cooled down to 18°C and 
NaBH4 (0.163 mol, 6.2 g) was added portionwise over about 30 minutes. At 
the end of the addition, the resulting reaction mixture was stirred at 20°C for 
4 hours. At the end of the reaction charcoal (5 g) was added, the mixture 
was filtered on a Celite® pad and the filter washed with methanol/water 2:1 
(2x20 mL). To the resulting solution acetic acid (0.707 mol, 40.5 mL) was 
added dropwise over a period of 30 minutes. Precipitation of the product 
was observed. The solid was filtered, washed with methanol/water 2:1 
(2x40 mL) and dried in a vacuum oven to give fexofenadine (15.4, 132.1 g, 
97% yield) as a white solid. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.54 (d, 4H, J = 7.7 Hz), 7.29 (m, 
8H), 7.14 (t, 2H, J = 7.2 Hz), 4.88 (bs, >3H, 2xOH + NH + moisture), 4.53 (t, 
1H, J = 6.0 Hz), 2.88 (bs, 2H), 2.46 (bt, 1H, J = 10.7 Hz), 2.32 (bt, 2H, J = 
6.6 Hz), 1.99 (bt, 2H, J = 10.9 Hz), 1.64 (m, 2H), 1.52 (m, 4H), 1.49 (s, 6H), 
1.32 (bd, 2H, J = 12.2 Hz). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 178.3 (C), 147.2 (C), 144.4 (C), 
144.1 (C), 127.9 (CH), 125.8 (CH), 125.6 (CH), 125.3 (CH), 78.5 (C), 72.0 
(CH), 57.5 (CH2), 53.1 (CH2), 53.0 (CH2), 45.9 (C), 43.2 (CH), 37.4 (CH2), 
26.9 (CH3), 25.4 (CH2), 22.5 (CH2). 
MP 226.4°C (DSC). 
FT-IR (KBr): ṽ = 3640, 3324 (br), 3050, 3028, 2989, 2961, 2867, 3000-2200 
(br), 1664, 1624, 1578, 1499, 1447, 1390, 1324, 1165, 1067, 859, 755, 708 
cm-1. 
ESI-MS m/z 502.3 [M+H]+ (calcd for C32H39NO4, 501.3). 
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4.5.9 Synthesis of fexofenadine·HCl (1.4) 
To a solution of fexofenadine base (15.4, 0.263 mol, 132.1 g) in ethyl 
acetate (1320 mL) aqueous HCl (37%w/w, 0.289 mol, 23.9 mL) was added 
dropwise over a period of 30 minutes. At the end of the addition, a white 
solid starts to precipitate. The resulting suspension was stirred for 2 hours, 
in order to allow the complete precipitation of the product. The white solid 
was filtered and washed with ethyl acetate (3x50 mL) and dried in a 
vacuum oven at 45-50°C. The solid was suspended in acetone (780 mL) 
and heated to reflux for 5 hours. The reaction mixture was allowed to cool 
down to 40°C and was filtered. The solid was washed with acetone (3x50 
mL) and dried in a vacuum oven to give fexofenadine·HCl (1.4, 130.0 g, 
92% yield) as a white solid. 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 10.04 (bs, 1H), 7.52 (d, 4H, J = 
7.7 Hz), 7.29 (m, 8H), 7.16 (t, 2H, J = 7.2 Hz), 5.40 (bs, 1H), 4.56 (t, 1H, J = 
6.0 Hz), 3.36 (bs, 1H), 3.32-2.72 (m, 10H), 1.83 (m, 4H), 1.67 (m 2H), 1.49 
(s, 6H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 177.6 (C), 146.7 (C), 144.1 (C), 
143.5 (C), 128.0 (CH), 126.2 (CH), 125.8 (CH), 125.3 (CH), 78.3 (C), 71.3 
(CH), 56.1 (CH2), 51.6 (CH2), 45.5 (C), 41.0 (CH), 36.1 (CH2), 26.5 (CH3), 
24.0 (CH2), 20.0 (CH2). 
MP 168.9°C (DSC). 
FT-IR (KBr): ṽ = 3528, 3311, 3055, 3024, 2943, 2885, 3000-2450, 1716, 
1508, 1491, 1446, 1264, 750, 702 cm-1. 
ESI-MS m/z 502.3 [(M∙HCl)-Cl]+ (calcd for C32H40ClNO4, 537.3). 
1.4
COOH
H+
N
HO
Ph
Ph
OH
Cl-
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4.5.10 Synthesis of 4-(4-t-butylphenyl)but-3-yn-1-ol (17.4) 
A solution of 1-bromo-4-t-butylbenzene (16.4, 0.024 mol, 5.0 g) in 
triethylamine (0.059 mol, 8.2 mL) was stirred under nitrogen for 15 minutes. 
Triphenylphosphine (0.14 mmol, 37 mg) and CuI (0.12 mmol, 22 mg) were 
added and the reaction mixture was stirred until complete dissolution was 
obtained. To the resulting solution dichlorobis(triphenylphosphine) 
palladium(II) (0.05 mmol, 33 mg) was added and the reaction was heated to 
70°C. 3-Butyn-1-ol (0.026 mol, 2.0 mL) was added dropwise over a period 
of 4 hours. At the end of the addition the resulting reaction mixture was 
stirred at 70°C for 7 hours. The reaction mixture was allowed to warm to 
room temperature and toluene (15 mL) was added. Aqueous HCl (3.5M, 9 
mL) was added dropwise, maintaining the temperature under 30°C (slightly 
exothermic). At the end of the addition the phases were separated, and the 
organic layer was washed with water (3x9 mL). Charcoal (0.25 g) was 
added and the mixture was stirred for 30 minutes then was filtered off on a 
Celite® pad. The filter was washed with toluene (2x5 mL) and the solvent 
was removed under reduced pressure to give 4-(4-t-butylphenyl)but-3-yn-1-
ol (17.4, 4.5 g, 94% yield) as an orange oil. 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.34 (d, 2H, J = 8.9 Hz), 7.31 (d, 
2H, J = 8.9 Hz), 4.90 (t, 1H, J = 5.7 Hz), 3.59 (q, 2H, J = 3.6 Hz), 2.55 (t, 
2H, J = 6.9 Hz), 1.22 (s, 9H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 151.0 (C), 131.6 (CH), 125.8 
(CH), 120.9 (C), 88.2 (C), 81.6 (C), 60.5 (CH2), 34.9 (C), 31.5 (CH3), 23.9 
(CH2). 
FT-IR (KBr): ṽ = 3363, 2960, 2904, 2869, 1678, 1605, 1504, 1463, 1363, 
1269, 1109, 1044, 834 cm-1. 
ESI-MS m/z 202.1 [M+H]+ (calcd for C14H18O, 202.1). 
tBu
17.4
OH
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4.5.11 Synthesis of 4-bromo-1-(4-t-butylphenyl)butan-1-one (19.4) 
A solution of 4-(4-t-butylphenyl)but-3-yn-1-ol (17.4, 0.023 mol, 4.5 g) in 
methanol (10 mL) was cooled down to 10°C and aqueous HBr (48%w/w, 
0.023 mol, 1.3 mL) was added dropwise, maintaining the temperature 
below 25°C. At the end of the addition, the reaction mixture was heated to 
reflux temperature for 4 hours. The solution was then cooled down to room 
temperature and the solvent was removed under reduced pressure to give 
a mixture of 4-methoxy-1-(4-t-butylphenyl)butan-1-one (18.4) and 4-bromo-
1-(4-t-butylphenyl)butan-1-one (19.4) as a brown oil. A small aliquot of the 
mixture was subjected to column chromatography (eluant hexane-ethyl 
acetate 98:2), obtaining an analytical sample of 18.4. The whole residue 
was cooled down to 5°C and acetic HBr (33%w/w, 4.5 mL) was added 
dropwise, maintaining the temperature below 20°C. At the end of the 
addition the resulting mixture was stirred at room temperature for 4 hours. 
At the end of the reaction toluene (15 mL) and water (10 mL) were added. 
The phases were separated, and the product was extracted with toluene (5 
mL). The combined organic phases were washed with aqueous NaHCO3 
saturated solution (15 mL) and the solvent was removed under reduced 
pressure to give 4-bromo-1-(4-t-butylphenyl)butan-1-one (19.4, 5.9 g, 91% 
yield) as a brown oil. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.90 (d, 2H, J = 8.3 Hz), 7.47 (d, 
2H, J = 8.0 Hz), 3.37 (t, 2H, J = 6.4 Hz), 3.22 (s, 3H), 3.10 (t, 2H, J = 7.2 
Hz), 1.88 (quint, 2H, J = 6.7 Hz), 1.26 (s, 9H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 199.0 (C), 156.0 (C), 134.2 (C), 
127.8 (CH), 125.4 (CH), 71.1 (CH2), 57.8 (CH3), 34.7 (C), 34.5 (CH2), 30.8 
(CH3), 23.8 (CH2). 
FT-IR (KBr): ṽ = 2961, 2928, 2869, 1681, 1605, 1406, 1364, 1270, 1190, 
1117, 995, 840 cm-1. 
ESI-MS m/z 234.3 [M+H]+ (calcd for C15H22O2, 234.2). 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.88 (d, 2H, J = 8.3 Hz), 7.48 (d, 
2H, J = 8.6 Hz), 3.57 (t, 2H, J = 6.7 Hz), 3.13 (t, 2H, J = 6.9 Hz), 2.14 (quint, 
2H, J = 6.9 Hz), 1.25 (s, 9H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 197.9 (C), 156.1 (C), 133.9 (C), 
127.8 (CH), 125.4 (CH), 36.2 (CH2), 34.7 (C), 34.2 (CH2), 30.7 (CH3), 27.1 
(CH2). 
ESI-MS m/z 283.2/285.2 [M+H]+ (calcd for C14H19BrO, 282.1/284.1). 
tBu
O
MeO
18.4
tBu
O
Br
19.4
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4.5.12 Synthesis of 1-(4-bromo-1,1-dimethoxybutyl)-4-t-butylbenzene 
(20.4) 
To a solution of 4-bromo-1-(4-t-butylphenyl)butan-1-one (19.4, 0.021 mol, 
5.9 g) in methanol (10 mL) were added sulfuric acid (0.002 mol, 0.1 mL) 
and trimethylorthoformate (0.025 mol, 2.8 mL). The resulting solution was 
heated to reflux temperature for 2 hours. At the end of the reaction, the 
solution was cooled down to 20°C and methanolic NaOMe (30%w/w, 0.3 mL) 
was added. The solvent was evaporated under reduced pressure and 
toluene (20 mL) and water (10 mL) were added. The phases were 
separated, and the solvent was removed under reduced pressure to give 1-
(4-bromo-1,1-dimethoxybutyl)-4-t-butylbenzene (20.4, 6.1 g, 88% yield) as 
a brown oil. 
 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.39 (d, 2H, J = 8.3 Hz), 7.32 (d, 
2H, J = 8.3 Hz), 3.37 (t, 2H, J = 6.6 Hz), 3.07 (s, 6H), 1.98 (m, 2H), 1.45 
(quint, 2H, J = 8.0 Hz), 1.27 (s, 9H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 149.8 (C), 137.3 (C), 126.2 
(CH), 124.6 (CH), 102.5 (C), 48.0 (CH3), 36.1 (CH2), 34.6 (CH2), 34.1 (C), 
31.1 (CH3), 27.0 (CH2). 
ESI-MS m/z 329.1/330.2 [M+H]+ (calcd for C16H25BrO2, 328.1/330.1). 
 
 
tBu
20.4
OMeMeO
Br
 62 
 
4.5.13 Synthesis of (1-(4-(4-t-butylphenyl)-4,4-
dimethoxybutyl)piperidin-4-yl)diphenylmethanol (21.4) 
To a solution of NaHCO3 (0.027 mol, 2.2 g) and KI (0.002 mol, 0.32 g) in 
water (35 mL) azacyclonol (0.019 mol, 5.1 g) was added. A solution of 1-(4-
bromo-1,1-dimethoxybutyl)-4-t-butylbenzene (20.4, 0.019 mol, 6.1 g) in 
toluene (70 mL) was added and the resulting reaction mixture was heated 
to reflux for 5 hours. At the end of the reaction, the mixture was allowed to 
warm to room temperature and the phases were separated. The organic 
layer was washed with water (35 mL) and the organic solvent was removed 
under reduced pressure to give (1-(4-(4-t-butylphenyl)-4,4-
dimethoxybutyl)piperidin-4-yl)diphenylmethanol (21.4, 8.8 g, 90% yield) as 
a brownish oil. 
 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.49 (d, 4H, J = 7.6 Hz), 7.34 (s, 
4H), 7.24 (t, 4H, J = 7.5 Hz), 7.11 (t, 2H, J = 7.2 Hz), 4.92 (s, 1H), 3.07 (s, 
6H), 2.62 (bd, 2H, J = 10.7 Hz), 2.35 (bt, 1H, J = 11.5 Hz), 2.05 (t, 2H, J = 
6.7 Hz), 1.86 (bt, 2H, J = 8.0 Hz), 1.76 (bt, 2H, J = 11.2 Hz), 1.43 (qd, 2H, 
J1 = 11.7 Hz, J2 = 2.7 Hz), 1.28 (m, 11H), 1.08 (quint, 2H, J = 7.6 Hz). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 149.6 (C), 147.3 (C), 137.8 (C), 
127.6 (CH), 126.4 (CH), 125.8 (CH), 124.5 (CH), 103.2 (C), 78.5 (C), 57.6 
(CH2), 53.7 (CH2), 48.0 (CH3), 44.0 (CH), 34.3 (CH2), 34.1 (C), 31.1 (CH3), 
26.1 (CH2), 20.6 (CH2). 
FT-IR (KBr): ṽ = 3517, 3443, 3354, 3090, 3047, 3024, 2954, 2897, 2827, 
2808, 2769, 1652, 1447, 1121, 1065, 749, 703 cm-1. 
ESI-MS m/z 515.4 [M+H]+ (calcd for C34H45NO3, 515.3). 
21.4
tBu
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4.5.14 Synthesis of 1-(4-t-butylphenyl)-4-(4-
(hydroxydiphenylmethyl)piperidin-1-yl)butan-1-one (22.4) 
To a solution of (1-(4-(4-t-butylphenyl)-4,4-dimethoxybutyl)piperidin-4-
yl)diphenylmethanol (21.4, 0.016 mol, 8.0 g) in methanol (30 mL) aqueous 
HCl (37%w/w, 0.017 mol, 1.4 mL) was added dropwise over a period of 30 
minutes. The resulting solution was stirred for 1 hour. At the end of the 
reaction, aqueous NaHCO3 (30 mL) was added dropwise over a period of 
30 minutes, maintaining the temperature below 30°C (slightly exothermic). 
EtOAc (30 mL) was added and the phases were separated. The organic 
layer was washed with brine (15 mL) and the solvent was removed under 
reduced pressure to give 1-(4-t-butylphenyl)-4-(4-(hydroxydiphenylmethyl)-
piperidin-1-yl)butan-1-one (22.4, 7.4 g, 97% yield) as a colourless oil. 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.92 (d, 2H, J = 8.6 Hz), 7.57 (d, 
4H, J = 8.0 Hz), 7.53 (d, 2H, J = 8.2 Hz), 7.28 (t, 4H, J = 7.7 Hz), 7.15 (t, 
2H, J = 7.2 Hz), 2.98 (t, 2H, J = 7.0 Hz), 2.89 (bd, 2H, J = 7.0 Hz), 2.46 (bt, 
1H, J = 11.9 Hz), 2.36 (t, 2H, J = 6.9 Hz), 1.97 (bt, 2H, J = 10.9 Hz), 1.84 
(quint, 2H, J = 7.1 Hz), 1.56 (qd, 2H, J1 = 11.8 Hz, J2 = 2.0 Hz), 1.34 (m, 
11H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 199.0 (C), 155.6 (C), 147.0 (C), 
134.3 (C), 127.5 (CH), 127.3 (CH), 125.6 (CH), 125.4 (CH), 125.0 (CH), 
78.4 (C), 57.1 (CH2), 53.5 (CH2), 43.8 (CH), 35.5 (C), 34.4 (CH2), 30.5 
(CH3), 25.9 (CH2), 21.4 (CH2). 
FT-IR (KBr): ṽ = 3460, 1677, 1601, 822, 757 cm-1. 
ESI-MS m/z 470.3 [M+H]+ (calcd for C32H39NO2, 469.3) 
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5. Ravidasvir 
The work of the third year of the PhD was focused on the selected API 
ravidasvir 1.5 (Figure 1.5). 
 
Figure 1.5 - Ravidasvir 
This important API, commercialized as the hydrochloride and formerly 
known as PPI-668, is a novel Direct-Acting Antiviral (DAA) used for the 
treatment of chronic hepatitis C.  
Actually the molecule of ravidasvir is in Phase 3 clinical trials.[1.5] 
The aim of this work is to pursue an efficient and scalable preparation for 
this API, alternative to the existing synthetic protocols actually covered by 
patents. 
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5.1 Chronic hepatitis C 
The hepatitis C virus (HCV) is a major human pathogen. It causes chronic 
hepatitis C infection, a very important public health problem, with about 71 
million people worldwide living with one of the six major genotypes of 
HCV.[2.5,3.5] Each year, hepatitis C causes approximately 399.000 deaths 
worldwide, mostly from cirrhosis and hepatocellular carcinoma (HCC).[4.5] 
According to WHO (World Health Organization), about 3-4 million new 
cases of infection are annually reported. HCV is considered a major health 
issue, since the infection frequently progress to cirrhosis and liver cancer 
(Figure 2.5). The main cofactors influencing the progression of the disease, 
terminating with cirrhosis and HCC, are the metabolic syndrome and the 
alcohol abuse. Each year, liver transplantation is performed on about a third 
of patients with complication associated with infection by hepatitis C 
virus.[3.5] 
 
Figure 2.5 - Pathophysiology of HCV infection 
In addition to hepatic disease, HCV infection has also been found to causes 
a several number of extra-hepatic diseases, affecting eyes, joints, thyroid, 
salivary glands, nervous and immune systems, skin and kidneys. These 
extra-hepatic diseases produce an important burden for health care 
systems and society, since are reported in up to threequarters of the 
patients affected by HCV.[2.5] 
First therapy for HCV infection consisted in the use of pegylated interferon-
alpha (peg-IFN-), in monotherapy or in association with ribavirin (RBV). 
Due to the virus resistance and an high number of side effects of peg-IFN- 
and RBV, like fatigue, mood and sleep disorders, skin reaction, dyspnea 
and hematological disorders, a new therapy was needed for the treatment 
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of chronic hepatitis C. A new treatment based on Direct-Acting Antivirals 
(DAAs) opened the way to the viral eradication without substantial side 
effects in almost all infected patients.[2.5] 
 
5.2 Direct-Acting Antivirals for the treatment of HCV 
infection 
In 2011, boceprevir and telaprevir (first generation DAAs) were approved 
for the treatment of HCV infection. The mechanism of action of these two 
drugs consist in an inhibition of the non-structural protease NS3/4A, 
combined with peg-IFN- and RBV to prevent virus resistance. From early 
2014, the second generation of DAAs was introduced and classified in four 
drug classes on the base of their target of action: 
- NS3/4A protease inhibitors (e.g. simeprevir); 
- NS5B polymerase inhibitors, nucleoside analogues (e.g. 
mericitabine, sofosbuvir); 
- NS5B polymerase inhibitors, non-nucleoside analogues (e.g. 
setrobuvir, beclabuvir); 
- NS5A inhibitors (e.g. elbasvir, ledipasvir, daclatasvir, ravidasvir, 
Figure 3.5). 
Ravidasvir (PPI-668) is a very potent NS5A inhibitor for the treatment of 
chronic hepatitis C virus infection. 
After Phase 1 and 2 trials, this drug showed high efficacy, even in hardly 
treatable cirrhotic patients and proved to have an excellent margin of safety 
and tolerability.[1.5,5.5] 
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Figure 3.5 - NS5A inhibitors (-asvir) 
 
5.3 Results and discussion 
The strategies reported to date for the synthesis of ravidasvir hydrochloride 
1.5 are extremely conservative. Since this API is still in Phase 3 of the 
clinical trials, all the reported preparation shares the same precursor/key 
intermediates, according to the originator’s way of synthesis (Scheme 1.5). 
[6.5] 
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The two key retrosynthetic steps of these route of synthesis are: 
1) the introduction of the Moc protected L-Val-L-Pro (represented by 
compounds 2.5 and 7.5); 
2) the synthesis of the two intermediates 4.5 and 5.5 and subsequent 
coupling to generate the entire back-bone of the final product. 
 
 
Scheme 1.5 - Retrosynthetic strategy of the prior-art syntheses 
Initially, the double disconnection of two Moc-protected L-valine residues 
generates the compound 3.5, which contains two Boc-protected 
pyrrolidines sharing a stereocenter with the same chirality. These two 
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moieties are derived from the common previous ancestor, represented by 
Boc-protected L-proline 7.5. 
The intermediate 3.5 is then fragmented in two compounds: the 
benzimidazole 4.5 and the 5-naphthyl-imidazole 5.5, both suitably 
functionalized with selected functional groups. The choice of the halogen 
atom (X = -Br[7.5,8.5], -I[9.5]) on the benzimidazole 4.5 and a boronic group on 
the naphthyl residue of the compound 5.5, paves the way for their 
connection, performed through a Pd-catalyzed Suzuki coupling, generating 
the intermediate 3.5. 
The synthesis of the compound 4.5 is achieved by reacting 4-halo-1,2-
diaminobenzene 6.5 (X = -Br[7.5,8.5], -I[9.5]) with the Boc-protected L-proline 
7.5 (the latter representing the precursor of the chiral pyrrolidine moiety). By 
disconnection of the imidazole moiety of the compound 5.5, the -acyloxy 
ketone 8.5 was obtained. The latter was synthesized starting from the 
bromonaphthalene 9.5, by performing three reactions: Friedel-Crafts 
acylation, bromination of the obtained ketone and nucleophilic substitution 
with 7.5. The intermediate 8.5 can be transformed in the desired compound 
5.5 by a simple heterocyclization step, generating the imidazole ring. 
Another patent describes the possibility to exchange the halogen group and 
the boronic group, for the Suzuki reactions, between the compounds 3.5 
and 4.5.[10.5] 
All the starting materials used in these approaches are commercially 
available and cheap and for this reason, we decided to use some of them 
(e.g. the natural aminoacids L-valine and L-proline) to start with the search 
of a new and efficient synthetic way to ravidasvir hydrochloride 1.5.  
We explored the possibility to perform a different approach in the assembly 
of the molecular skeleton of ravidasvir. Previous approaches rely on a 
semiconvergent synthesis starting with the central core of ravidasvir, 
represented by the biarylmoiety (naphthalene-benzimidazole). The outer 
aminoacid-derived residues (pyrrolidine and Moc-L-valine) are then added 
in the final steps of the synthesis. 
Our approach is based on the observation that the outer parts of the 
molecule of ravidasvir share a common residue consisting in a Moc-L-Val-
pyrrolidine, the latter bearing two aminoacid-derived stereocenters (one 
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from L-Val and the stereocenter of the 2-substituted pyrrolidine ring arising 
from L-Pro). This common residue could be built as a key intermediate in a 
convergent synthesis, reducing the overall number of steps. Moreover, this 
alternative strategy has the additional advantage of avoiding claimed 
intermediates, generating instead new and patentable compounds. 
The synthesis starts with a simple protection of the commercially available 
L-valine by using methyl chloroformate, NaHCO3 as base in a 
water/tetrahydrofuran mixture (Scheme 2.5). After 18 hours of reaction at 
room temperature, the Moc-protected L-valine 2.5 was obtained in high 
yield (94%).  
The following step is the formation of a peptide bond between 2.5 and the 
natural aminoacid L-proline. The carboxylic group of the proline must be 
protected (e.g. as ester), in order to avoid the generation of byproducts 
(arising for example from the homo-coupling); the commercially available L-
proline benzyl ester hydrochloride was then used. After the treatment with 
triethylamine, necessary to generate the proline free base, the condensing 
agent T3P® (commercially available as acetonitrile solution) succeeded in 
the formation of the intermediate 11.5 (40°C, 3 hours, 81% yield). 
 
Scheme 2.5 - Synthesis of the novel key intermediate 12.5 
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Hydrogenation of the benzyl ester of 11.5 was performed by using 
ammonium formate as the hydrogen donor, in the presence of palladium on 
carbon as the catalyst, in refluxing methanol for 5 hours. The Moc-protected 
dipeptide 12.5 was isolated in 87% yield (final step) and 66% overall 
yield.[11.5] This compound represent the first important key intermediate, 
clearly recognizable in both the distal portions of the molecule of ravidasvir. 
This result paves the way to the development of the second part of the 
synthesis, involving the preparation of the two aryl “partners” for the Suzuki 
couplingen route to the biaryl core. 
The synthesis of the first compound (Scheme 3.5), for the Suzuki reaction, 
started with the trifluoromethanesulfonation of the cheap starting material 
13.5, achieved by using trifluoromethanesulfonic anhydride, triethylamine 
as base in toluene at -5°C for 1 hour. The corresponding 
trifluoromethanesulfonate 14.5 was obtained in 89% yield. The functional 
group aryl-triflate, introduced in this reaction, can be used in the last 
synthetic step instead of the halogen group, as reported in literature.[12.5,13.5] 
Bromination of the keto group of the compound 14.5 was performed with N-
bromosuccinimide in methanol, in the presence of catalytic HBr/AcOH 
(45°C, 16 h, 89% yield). The corresponding -bromoketone 15.5 bearing 
the leaving group for the subsequent nucleophilic substitution of the 
dipeptide 12.5. This reaction ran in 2-butanone at room temperature for 16 
hours, with triethylamine as base. The product 16.5, almost quantitatively 
obtained (98% yield), contains an -acyloxyketone group which has the role 
of precursor of the imidazole moiety, present in the final API. 
Cyclization of the -acyloxyketone 16.5 was achieved by using ammonium 
acetate in toluene at 90°C. After 5 hours of reaction, the corresponding 
naphthylimidazole 17.5 was isolated in a good yield (90%), representing the 
first key intermediate for the final coupling. 
The second key intermediate was prepared starting with the commercially 
available at low price 4-bromo-1,2-diaminobenzene 18.5. The latter was 
reacted with the dipeptide 12.5, generating the benzoimidazole 19.5. This 
synthetic step was performed with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride as condensing agent and 
tetrahydrofuran as solvent (room temperature, 1.5 hours, 92% yield). 
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The subsequent step consisted in the transformation of the bromide group 
of the compound 19.5 in a suitable boronic group. We found in literature 
that the boronic esters have good reactivity in the Suzuki coupling[14.5] and 
are also very simple to prepare. 
 
Scheme 3.5 - New synthetic route of ravidasvir hydrochloride 1.5 
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We choose bis(pinacolate)diboron as the reagent to perform this 
transformation, since it is commercially available and relatively cheap. By 
using the conditions reported in Scheme 3.5 (potassium acetate, sodium 
bicarbonate as base, [1,1′-bis(diphenylphosphino)ferrocene]dichloro-
palladium(II) as catalyst, refluxing 2-propanol, 1.5 hours), the corresponding 
pinacol boronic ester  20.5 was obtained in 92% yield. 
We finalized the last synthetic step of this original preparation of the 
selected API by mixing the two key intermediates 17.5 and 20.5, in the 
presence of potassium hydrogen phosphate and catalytic [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II). After 4 hours of 
reaction (60°C in a water/methanol solvent mixture), ravidasvir free base 
was obtained and subsequently salified as hydrochloride (crude 1.5) by 
treatment with a solution of HCl in 2-propanol (20%w/w).  
Final crystallization in a mixture 2-propanol/acetone led to analytically pure 
ravidasvir hydrochloride 1.5, collected by simple filtration as white 
crystalline powder, in 80% yield (referred to final step and purification).[11.5] 
 
5.4 Conclusion and future developments 
In the final year of the PhD we developed an efficient and scalable synthetic 
approach for the preparation of the important NS5A inhibitor ravidasvir 
hydrochloride 1.5, for the treatment of chronic hepatitis C virus infection. 
This novel synthesis is based on the preparation of a key dipeptide 12.5, 
used for the subsequent generation of other two advanced intermediates 
17.5 and 20.5, finally connected to obtain the desired product. This 
synthetic strategy significantly reduces the number of the synthetic steps (8 
vs 11) and circumvents existing patents by introducing the Moc-L-valine-L-
proline moiety before the Pd-catalyzed Suzuki coupling. Moreover, the 
isolation of all intermediate and the final product requires only simple work-
up procedures and avoids chromatographic separations, allowing the entire 
protocol to be transferred on a kilolab scale then on the industrial scale. 
The overall yield of the above described process is 46%,[11.5] referred to the 
longest linear step.  
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5.5 Experimental section 
5.5.1 Material and methods 
The chemicals used for the experiments were of the highest analytical 
grade. Nuclear magnetic resonance spectra (1H, 13C-NMR) were recorded 
on a JEOL ECP300 (7.04 T) spectrometer or a Bruker Avance Neo (9.4 T) 
spectrometer. Chemical shifts (δ) are quoted in parts per million (ppm) and 
referenced to the residual solvent peak. Coupling constants (J) are quoted 
in Hertz (Hz). Mass spectra (MS) were recorded on a Thermo Finnigan 
TSQ700 triple-quadrupole instrument equipped with an electrospray 
ionization source. 
 
5.5.2 Synthesis of (S)-2-(methoxycarbonylamino)-3-methylbutanoic 
acid (2.5) 
To a suspension of L-valine (10.5, 0.85 mol, 100.0 g) in tetrahydrofuran 
(500 mL), water (500 mL) and NaHCO3 (2.65 mol, 215.1 g) were added and 
the resulting mixture was cooled down to 15°C. Methyl chloroformate (1.02 
mol, 79.3 mL) was added dropwise and the resulting suspension was 
stirred at room temperature for 18 hours. At the end of the reaction, aq. HCl 
(37%w/w, 79.3 mL) was added dropwise. The phases were separated, and 
the organic layer was washed with saturated aq. NaCl (100 mL), dried over 
MgSO4, filtered and the solvent was removed under reduced pressure to 
give (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (2.5, 141.0 g, 
94% yield) as a white solid. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 12.50 (bs, 1H), 7.23 (d, 1H, J = 
8.6 Hz), 3.86 (bt, 1H, J = 7.2 Hz), 3.54 (s, 3H), 2.03 (m, 1H), 0.88 (d, 3H, J 
= 5.8 Hz), 0.86 (d, 3H, J = 6.1 Hz). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 173.5 (C), 157.2 (C), 59.7 (CH), 
51.6 (CH3), 29.8 (CH), 19.3 (CH3), 18.1 (CH3). 
ESI-MS m/z 176.3 [M+H]+ (calcd for C7H13NO4, 175.2).  
 
5.5.3 Synthesis of (S)-benzyl 1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylate (11.5) 
To a suspension of (S)-benzyl pyrrolidine-2-carboxylate hydrochloride (0.37 
mol, 89.7 g) and (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (2.5, 
0.37 mol, 65.0 g) in acetonitrile (180 mL), triethylamine (1.48 mol, 207.0 
mL) was added dropwise maintaining the temperature below 25°C. T3P® 
solution (50%w/w in acetonitrile, 0.44 mol, 381.8 mL) was added dropwise 
and the resulting suspension was heated to 40°C for 3 hours. At the end of 
the reaction the solvent was removed under reduced pressure and ethyl 
acetate (450 mL) and water (200 mL) were added. The phases were 
separated and the organic layer was washed with water (100 mL), aq. HCl 
(2N, 100 mL), saturated aq. NaHCO3 (100 mL) and saturated aq. NaCl (100 
mL). The organic phase was dried over MgSO4, filtered and the solvent was 
removed under reduced pressure to give (S)-benzyl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate (11.5, 
108.1 g, 81% yield) as a white solid. 
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1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 7.36 (m, 6H), 5.13 (s, 2H), 4.41 
(q, 1H, J = 4.4 Hz), 4.05 (t, 1H, J = 8.5 Hz), 3.82 (q, 1H, J = 7.5 Hz), 3.60 
(q, 1H, J = 7.5 Hz), 3.53 (s, 3H), 2.19 (m, 1H), 1.89 (m, 4 H), 0.89 (m, 6H).  
13C-NMR (100.6 MHz, d6-DMSO): δ (ppm) = 171.7 (C), 170.6 (C), 156.8 
(C), 136.0 (C), 128.4 (2xCH), 128.0 (CH), 127.8 (2xCH), 65.8 (CH2), 58.6 
(CH), 57.8 (CH), 51.4 (CH3), 46.9 (CH2), 29.9 (CH), 28.8 (CH2), 24.6 (CH2), 
18.7 (CH3), 18.5 (CH3). 
ESI-MS m/z 363.5 [M+H]+ (calcd for C19H26N2O5, 362.4). 
 
5.5.4 Synthesis of (S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylic acid (12.5) 
To a solution of (S)-benzyl 1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylate (11.5, 0.22 mol, 79.0 g) in 
methanol (550 mL), ammonium formate (0.38 mol, 23.8 g) and palladium 
on carbon (10%w/w, 0.01 mol, 16.2 g) were added and the resulting 
suspension was heated to reflux temperature for 5 hours. At the end of the 
reaction, the mixture was cooled down to room temperature and filtered on 
a Celite® pad. The solvent was removed under reduced pressure then ethyl 
acetate (300 mL) and water (50 mL) were added. The phases were 
separated and the organic layer was washed with water (2x50 mL), dried 
over MgSO4, filtered and the solvent was removed under reduced pressure 
to give (S)-1-((S)-2-(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-
2-carboxylic acid (12.5, 52.0 g, 87% yield) as a white solid. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 7.25 (d, 1H, J = 8.2 Hz), 4.25 (m, 
1H), 4.03 (t, 1H, J = 8.1 Hz), 3.78 (m, 1H), 3.56 (m, 1H), 3.52 (s, 3H), 2.13 
(m, 1H), 1.90 (m, 4H), 0.93 (d, 3H, J = 6.4 Hz), 0.88 (d, 3H, J = 6.4 Hz).  
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 173.4 (C), 170.5 (C), 156.9 (C), 
58.7 (CH), 57.9 (CH), 51.5 (CH3), 47.0 (CH2), 30.1 (CH), 28.9 (CH2), 24.7 
(CH2), 18.9 (CH3), 18.6 (CH3). 
ESI-MS m/z 273.4 [M+H]+ (calcd for C12H20N2O5, 272.3). 
 
5.5.5 Synthesis of 6-acetylnaphthalen-2-yl trifluoromethanesulfonate 
(14.5) 
A solution of 1-(6-hydroxynaphthalen-2-yl)ethanone (13.5, 1.61 mol, 300.0 
g), triethylamine (2.09 mol, 291.7 mL) and toluene (3000 mL) was cooled 
down to -5°C and trifluoromethanesulfonic anhydride (1.77 mol, 297.6 mL) 
was added dropwise, maintaining the temperature below -2°C, and then 
was stirred for 1 hours. At the end of the reaction, water (750 mL) was 
added and the resulting mixture was allowed to warm to room temperature 
and the phases were separated. The organic layer was washed with aq. 
Na2CO3 (10% w/w, 750 mL), aq. HCl (2N, 750 mL) and saturated aq. NaCl 
(750 mL). The organic phase was then filtered on a Celite®/charcoal pad 
and the solvent was removed under reduced pressure to give 6-
acetylnaphthalen-2-yl trifluoromethanesulfonate (14.5, 456.7 g, 89% yield) 
as a brownish solid. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 8.67 (s, 1H), 8.25 (d, 1H, J = 9.0 
Hz), 8.06 (m, 3H), 7.61 (bd, 1H, J = 9.0 Hz), 2.67 (s, 3H). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 189.5 (C), 148.3 (C), 135.2 (C), 
135.1 (C), 132.8 (CH), 131.4 (C), 130.1 (CH), 128.5 (CH), 125.1 (CH), 
120.4 (CH), 119.3 (CH), 118.3 (CF3, J = 321 Hz), 26.6 (CH3). 
ESI-MS m/z 319.4 [M+H]+ (calcd for C13H9F3O4S, 318.3).  
 
5.5.6 Synthesis of 6-(2-bromoacetyl)naphthalen-2-yl 
trifluoromethanesulfonate (15.5) 
A solution of 6-acetylnaphthalen-2-yl trifluoromethanesulfonate (14.5, 1.41 
mol, 450.0 g) and acetic HBr (33%w/w, 0.14 mol, 34.6 g) in methanol (4500 
mL) was heated to 45°C. N-Bromosuccinimide (1.84 mol, 327.1 g) was 
added portionwise and the resulting mixture was stirred for 16 hours. At the 
end of the reaction the solution was cooled down to 15°C and water (5000 
mL) was added. The resulting suspension was filtered and the solid was 
washed with water (3x1000 mL). The solid was dissolved in 2-butanone 
and aq. HBr (62%w/w, 0.63 mol, 83 mL) was added. The resulting solution 
was stirred at room temperature for 16 hours then was washed with water 
(3x1500 mL) and saturated aq. NaCl (1500 mL). The organic phase was 
dried with Na2SO4, filtered and the solvent was removed under reduced 
pressure. 2-Propanol (1350 mL) was added and the suspension was 
heated to 55°C until complete dissolution then cooled down to 10°C. 
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Precipitation of the product starts and the suspension was stirred for 30 
minutes. The solid was filtered and washed with cold 2-propanol (3x100 
mL). The solid was dried in a vacuum oven to give 6-(2-
bromoacetyl)naphthalen-2-yl trifluoromethanesulfonate (15.5, 495.0 g, 89% 
yield) as a white solid. 
 
 
 
1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 8.84 (s, 1H), 8.31 (d, 1H, J = 8.8 
Hz), 8.20-8.08 (m, 3H), 7.68 (dd, 1H, J1 = 9.2 Hz, J2 = 1.8 Hz), 5.07 (s, 2H).  
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 191.4 (C), 148.5 (C), 135.4 (C), 
132.8 (CH), 132.4 (C), 131.2 (C), 130.6 (CH), 128.8 (CH), 125.5 (CH), 
120.7 (CH), 119.4 (CH), 118.3 (CF3, J = 321 Hz), 33.9 (CH2). 
ESI-MS m/z 397.3/399.3 [M+H]+ (calcd for C13H8BrF3O4S, 396.2/398.2).  
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5.5.7 Synthesis of (S)-2-oxo-2-(6-
(trifluoromethylsulfonyloxy)naphthalen-2-yl)ethyl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate 
(16.5) 
To a solution of 6-(2-bromoacetyl)naphthalen-2-yl trifluoromethanesulfonate 
(15.5, 1.01 mol, 400.0 g) and (S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylic acid (12.5, 1.21 mol, 331.2 g) in 2-
butanone (4000 mL), triethylamine (1.01 mol, 139.6 mL) was added 
dropwise in about 5 hours, maintaining the temperature below 25°C. At the 
end of the addition, the resulting suspension was stirred for 16 hours. At the 
end of the reaction HCl 2N (1000 mL) was added. The phases were 
separated and the organic layer was washed with saturated aq. NaHCO3 
(3x1000 mL) and saturated aq. NaCl (1000 mL). The solvent was removed 
under reduced pressure to give (S)-2-oxo-2-(6-
(trifluoromethylsulfonyloxy)naphthalen-2-yl)ethyl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate (16.5, 
581.0 g, 98% yield) as an orange oil. 
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1H-NMR (300 MHz, d6-DMSO): δ (ppm) = 8.78 (s, 1H), 8.29 (d, 1H, J = 9.0 
Hz), 8.16 (s, 1H), 8.03 (d, 1H, J = 9.0 Hz), 7.66 (dd, 1H, J1 = 8.7 Hz, J2 = 
1.8 Hz), 7.37 (d, 1H, J = 8.2 Hz), 4.65 (q, 2H, J = 5.5 Hz), 4.56 (m, 1H), 
4.03 (m, 2H), 3.80 (m, 1H), 3.54 (s, 3H), 2.28 (m, 1H), 1.98 (m, 4H), 0.91 
(d, 3H, J = 7.3 Hz), 0.88 (d, 3H, J = 8.0 Hz). 
13C-NMR (75.6 MHz, d6-DMSO): δ (ppm) = 192.7 (C), 171.7 (C), 171.0 (C), 
157.1 (C), 148.7 (C), 135.8 (C), 133.1 (CH), 132.4 (C), 131.5 (C), 130.0 
(CH), 129.1 (CH), 124.9 (CH), 121.0 (CH), 119.7 (CH), 118.5 (CF3, J = 323 
Hz), 66.8 (CH2), 58.6 (CH), 58.0 (CH), 51.7 (CH3), 47.2 (CH2), 30.1 (CH), 
29.0 (CH2), 24.7 (CH2), 18.8 (CH3), 18.6 (CH3). 
ESI-MS m/z 589.7 [M+H]+ (calcd for C25H27F3N2O9S, 588.6).  
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5.5.8 Synthesis of 6-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)naphthalen-2-yl 
trifluoromethanesulfonate (17.5) 
To a solution of 1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylate (16.5, 0.780 mol, 460.0 g) in 
toluene (4600 mL), ammonium acetate (2.73 mol, 210.4 g) was added and 
the resulting suspension was heated at 90°C for 5 hours. At the end of the 
reaction, the solution was cooled down to room temperature and water 
(3000 mL) and NaHCO3 (300 g) were added. The phases were separated 
and the organic layer was washed with water (2x1000 mL) and saturated 
aq. NaCl (1000 mL). The organic layer was filtered on a Celite®/charcoal 
pad and the filter was washed with toluene (3x500 mL). The solvent was 
removed under reduced pressure to give 6-(2-((S)-1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-
yl)naphthalen-2-yl trifluoromethanesulfonate (17.5, 398.0 g, 90% yield) as a 
pale yellow solid. 
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1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 11.92 (bs, 1H), 8.33 (s, 1H), 8.04 
(m, 4H), 7.68 (s, 1H), 7.53 (dd, 1H, J1 = 8.9 Hz, J2 = 1.9 Hz), 7.30 (d, 1H, J 
= 8.4 Hz), 5.15 (m, 1H), 4.12 (t, 1H, J = 8.2 Hz), 3.85 (bs, 2H), 3.57 (s, 3H), 
2.18 (m, 2H), 2.08 (m, 3H), 0.94 (d, 3H, J = 6.7 Hz), 0.88 (d, 3H, J = 6.6 
Hz).  
13C-NMR (100.6 MHz, d6-DMSO): δ (ppm) = 170.5 (C), 156.9 (C), 146.2 
(C), 132.7 (2xC), 131.6 (2xC), 131.5 (C), 130.6 (2xCH), 128.2 (CH), 125.3 
(CH), 121.3 (CH), 119.8 (CH), 119.2 (CH), 118.8 (CF3, J = 318 Hz), 58.1 
(CH), 54.4 (CH), 51.4 (CH3), 46.9 (CH2), 30.9 (CH2), 29.9 (CH), 24.4 (CH2), 
19.0 (CH3), 18.5 (CH3). 
ESI-MS m/z 569.7 [M+H]+ (calcd for C25H27F3N4O6S, 568.6).  
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5.5.9 Synthesis of (S)-5-bromo-1H-benzo[d]imidazol-2-yl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate 
(19.5) 
A solution of (S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylic acid (12.5, 0.367 mol, 100.0 g) and 
4-bromobenzene-1,2-diamine (18.5, 0.367 mol, 68.5 g) in tetrahydrofuran 
(500 mL) was cooled down to 0°C. 3-(Ethyliminomethyleneamino)-N,N-
dimethylpropan-1-amine hydrochloride (0.380 mol, 73.6 g) was added and 
the resulting mixture was stirred at room temperature for 1.5 hours. At the 
end of the reaction the solvent was removed under reduced pressure and 
ethyl acetate (850 mL) and water (250 mL) were added. The biphasic 
mixture was filtered on a Celite® pad then the phases were separated. The 
organic layer was washed with water (150 mL) and saturated aq. NaCl (150 
mL) and the solvent was removed under reduced pressure to a residue of 
about 300 mL. Acetic acid (0.75 mol, 42.9 mL) was added and the resulting 
solution was heated to reflux temperature for 2.5 hours. At the end of the 
reaction, the mixture was cooled down to room temperature and ethyl 
acetate (700 mL), water (250 mL) and NaHCO3 (100.0 g) were added. The 
phases were separated, and the organic layer was washed with water (200 
mL) and saturated aq. NaCl (200 mL) and the solvent was removed under 
reduced pressure. The obtained residue was dissolved in methyl t-butyl 
ether (300 mL) and the solution was added dropwise to heptane (1300 mL). 
The suspension was stirred for 1 hour to maximize the precipitation of the 
product. The solid was filtered and washed with heptane/methyl t-butyl 
ether mixture (4:1, 250 mL) to give methyl (S)-1-((S)-2-(5-bromo-1H-
benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate 
(19.5, 139.4 g, 90% yield) as a white solid. 
 
 88 
 
 
 
1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 12.39 (bs, 1H), 7.68 (s, 1H), 7.45 
(d, 1H, J = 8.5 Hz), 7.27 (m, 2H), 5.19 (m, 1H), 4.09 (t, 1H, J = 8.3 Hz), 3.85 
(m, 2H), 3.55 (s, 3H), 2.21 (m, 2H), 2.00 (m, 3H), 0.85 (d, 3H, J = 7.3 Hz), 
0.83 (d, 3H, J = 8.2 Hz). 
13C-NMR (100.6 MHz, d6-DMSO): δ (ppm) = 170.7 (C), 157.2 (C), 156.9 
(C), 124.2 (3xCH), 113.6 (C), 66.4 (C), 58.0 (CH), 54.7 (CH), 51.5 (CH3), 
47.0 (CH2), 30.9 (CH2), 29.7 (CH), 24.5 (CH2), 19.1 (CH3), 18.4 (CH3). 
ESI-MS m/z 423.4/425.4 [M+H]+ (calcd for C18H23BrN4O3, 422.3/424.3).  
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5.5.10 Synthesis of (S)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-benzo[d]imidazol-2-yl 1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylate (20.5) 
To a solution of (S)-5-bromo-1H-benzo[d]imidazol-2-yl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate (19.5, 
0.472 mol, 200.0 g) and 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-
dioxaborolane) (0.567 mol, 144.0 g) in 2-propanol (1600 mL), potassium 
acetate (0.944 mol, 92.8 g), NaHCO3 (0.472 mol, 39.7 g), [1,1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with 
dichloromethane, 0.009 mol, 7.71 g) and water (0.472 mol, 8.5 mL) were 
added. The resulting mixture was heated to reflux temperature for 1.5 
hours. At the end of the reaction, the mixture was cooled down to room 
temperature and water (1400 mL) and toluene (1000 mL) were added. The 
phases were separated and water (800 mL) and aq. HCl (37%w/w, 500 mL) 
were added. The biphasic mixture was filtered on a Celite®/charcoal pad 
and the filter was washed with aq. HCl (2N, 2x400 mL). The phases were 
separated and dichloromethane (1000 mL) and NaHCO3 (1.424 mol, 80.0 
g) were added to the aqueous layer. The phases were separated, the 
organic layer was washed with aq. NaCl (2N, 400 mL) and the solvent was 
removed under reduced pressure to give  (S)-5-(4,4,5,5-tetramethyl-1,3,2-
dioxaborolan-2-yl)-1H-benzo[d]imidazol-2-yl 1-((S)-2-
(methoxycarbonylamino)-3-methylbutanoyl)pyrrolidine-2-carboxylate (20.5, 
205.2 g, 92% yield) as a yellowish solid. 
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1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 12.25 (d, 1H, J = 16.0 Hz), 7.81 
(d, 1H, J = 22.7 Hz), 7.49 (m, 2H), 7.29 (d, 1H, J = 6.3 Hz), 5.21 (bs, 1H), 
4.10 (t, 1H, J = 8.2 Hz), 3.87 (m, 2H), 3.56 (s, 3H), 2.24 (m, 2H), 1.98 (m, 
3H), 1.29 (s, 12H), 0.84 (m, 6H). 
13C-NMR (100.6 MHz, d6-DMSO): δ (ppm) = 170.6 (C), 156.9 (C), 145.6 
(C), 142.8 (C), 136.6 (C), 133.9 (C), 127.9 (CH), 127.0 (CH), 125.3 (CH), 
83.4 (C), 83.3 (C), 58.0 (CH), 54.8 (CH), 51.5 (CH3), 47.0 (CH2), 30.9 
(CH2), 29.8 (CH), 24.7 (4xCH3), 24.5 (CH2), 19.0 (CH3), 18.4 (CH3). 
ESI-MS m/z 471.5 [M+H]+ (calcd for C24H35BN4O5, 470.4).  
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5.5.11 Synthesis of ravidasvir hydrochloride (1.5) 
To a solution of (S)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-
benzo[d]imidazol-2-yl 1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidine-2-carboxylate (20.5, 0.893 mol, 420.0 g) in 
methanol (11000 mL) 6-(2-((S)-1-((S)-2-(methoxycarbonylamino)-3-
methylbutanoyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)naphthalen-2-yl 
trifluoromethanesulfonate (17.5, 0.616 mol, 350.0 g), K2HPO4 (1.540 mol, 
268.3 g), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) 
(complex with dichloromethane, 0.031 mol, 25.2 g) and water (1200 mL) 
were added and the resulting mixture was heated to 60°C for 4 hours. At 
the end of the reaction, the mixture was cooled down to 40°C and filtered 
on a Celite®/charcoal pad and the filter was washed with methanol (2x900 
mL). The solvent was removed under reduced pressure, dichloromethane 
(5000 mL) was added and the phases were separated. The organic layer 
was washed with water (1500 mL). HCl in 2-propanol (20%w/w, 200.0 g) was 
added and the solvent was removed under reduced pressure to give crude 
ravidasvir hydrochloride 1.5. The crude product was suspended in 2-
propanol (1500 mL) and the suspension was heated to reflux temperature 
until compete dissolution. The resulting solution was cooled down to 60°C 
and acetone/water (99:1, 2000 mL) was added dropwise during a period of 
1 hours. The mixture was stirred for 2 hours, allowing the complete 
precipitation of the product. The solid was filtered and washed with acetone 
(3x600 mL) to give pure ravidasvir hydrochloride (1.5, 412.0 g, 80% yield) 
as a white solid. 
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1H-NMR (400 MHz, d6-DMSO): δ (ppm) = 15.65 (bs, 1H), 15.12 (bs, 1H), 
8.65 (s, 1H), 8.28 (d, 2H, J = 3.3 Hz), 8.10 (m, 3H), 7.93 (m, 4H), 7.31 (d, 
1H, J = 8.2 Hz), 7.27 (d, 1H, J = 8.3 Hz), 5.38 (t, 1H, J = 6.4 Hz), 5.31 (t, 
1H, J = 6.4 Hz), 4.20 (m, 2H), 4.13 (m, 2H), 3.85 (bs, 2H), 3.55 (s, 6H), 2.42 
(m, 4H), 2.24 (m, 6H), 2.05 (m, 2H), 0.86 (d, 6H, J = 6.2 Hz), 0.77 (d, 6H, J 
= 4.7 Hz). 
13C-NMR (100.6 MHz, d6-DMSO): δ (ppm) = 171.2 (C), 171.0 (C), 157.0 
(2xC), 155.6 (C), 149.6 (C), 137.7 (C), 137.6 (C), 133.0 (C), 132.1 (C), 
131.6 (C), 130.5 (C), 129.3 (CH), 128.9 (CH), 126.4 (CH), 125.9 (CH), 
125.2 (CH), 124.9 (C), 124.0 (CH), 123.7 (CH), 112.4 (CH), 114.5 (CH), 
111.9 (CH), 57.9 (CH), 57.8 (CH), 53.5 (CH), 52.9 (CH), 51.6 (2xCH3), 47.3 
(2xCH2), 31.1 (2xCH2), 29.0 (2xCH), 25.1 (2xCH2), 19.8 (CH3), 19.7 (CH3), 
17.8 (CH3), 17.7 (CH3). 
ESI-MS m/z 836.9 [M+H]+ (calcd for C43H52Cl2N8O8, 835.8). 
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6. Discussion 
Active Pharmaceutical Ingredients were the main subject of this PhD in 
Chemistry & Biology. The work was focused on the research and 
development of innovative, efficient and convenient synthetic processes for 
the preparation of APIs. IP issues had to be tackled, too, avoiding claimed 
compounds and problems related to the originator’s way of synthesis. 
After the selection of the API, we started with the design of novel synthetic 
strategies for the selected molecules and we tested them in the laboratory 
on a small scale. In this thesis, for the sake of conciseness, we usually 
report, among the many different synthetic routes explored for the selected 
APIs, the one giving the best results in terms of overall yield, purity of the 
final molecule and costs. 
In a second time all the steps of the reported syntheses were scaled up to a 
10-100 g scale, in order to gain additional information required for the 
following transfer of the manufacturing methods to the industrial scale. 
 
6.1 Chapter 3 - Vildagliptin 
During the first year, the work was centered on the important API 
vildagliptin, currently employed for the treatment of type 2 diabetes mellitus. 
The critical step of the actual syntheses was the SN2 reaction between halo 
acylproline derivatives and 3-amino-1-adamantanol. This nucleophilic 
displacement gave a hardly separable mixture of the desired product 
vildagliptin and of bis-alkylation byproducts, with complex work-up 
procedures and a drop in the overall yield of the process. 
To avoid these issues and to prevent the formation of byproducts, we 
designed a synthesis based on a one-pot formylation and 
carboxymethylation of the nitrogen atom of the 3-amino-1-adamantanol. 
This represented the best alternative for the simultaneous introduction of 
the C2-linker moiety on the nitrogen atom and a formyl- as a protecting 
group, leading to a key monoalkylated-monoformylated intermediate and 
completely avoiding the formation of the bis-alkylated compounds. 
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By using this approach, we developed a 4-step scalable synthesis for 
vildagliptin, with high overall yield (63%) and simple isolation of the final 
product. We ran the entire synthetic protocol on a 200 g scale. 
6.2 Chapter 4 - Fexofenadine  
Fexofenadine hydrochloride, an API largely employed for the treatment of 
allergic rhinitis, was the target of the second year of the PhD.  
The syntheses reported to date share a common intermediate bearing an 
alkyne moiety as a precursor of the hydroxyl group contained in the final  
molecule. The key step of the transformation of the functional group of this 
intermediate is represented by the hydration of the C≡C triple bond. 
Reported protocols for this reaction usually require harsh conditions and 
toxic reagents (HgO/H2SO4 or Cu(BF4)2 in refluxing methanol), hardly 
compatible with large scale production. 
With the aim to eliminate the use of toxic metal ions, we started to study an 
alternative protocol for this alkyne hydration and we found that treatment of 
an intermediate alkynol with aqueous HBr gave a mixture of two products, 
identified as a -methoxyketone and a -bromoketone. Subsequent reaction 
with HBr in acetic acid, achieved the conversion of this raw mixture toward 
a single product, represented by the abovementioned -bromoketone. The 
latter represented the key intermediate for the preparation of fexofenadine 
hydrochloride, obtained with a 8-step synthesis in a satisfying 59% overall 
yield. 
Additional work involved: i) the scale up of this new route of synthesis to a 
100 g scale, ii) the mechanistic analysis of the new hydration reaction 
highlighting, the important role of the OH group of the alkynol in assisting 
intramolecularly the addition to the alkyne C≡C triple bond. Moreover, to 
test the generality of this transformation, the protocol was successfully 
adapted to the preparation of a cognate API (terfenadine hydrochloride). 
 
6.3 Chapter 5 - Ravidasvir 
The third year of the PhD was focused on a member of a novel class of 
Direct-Acting Antivirals (NS5A inhibitors, -asvir), recently introduced for the 
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treatment of hepatitis C virus infection, represented by ravidasvir 
hydrochloride. 
The strategies reported to date for the synthesis of this rather complex 
molecule were based on a semiconvergent synthesis, starting with the 
assembly of the central core of the molecule, represented by a biaryl moiety 
(benzimidazole-naphthalene). The two external residues, connected to the 
two extremities of the core, are composed by aminoacid-derived residues 
(pyrrolidine and Moc-L-Val) and are added in the final step of the synthesis.  
We observed that the outer moieties of ravidasvir share the same 
substructure and stereochemistry and for this reason we explored the 
possibility to build this common residue as a key and early intermediate, to 
be used in a convergent synthesis, allowing to reduce the overall number of 
steps and relying on new and patentable intermediates. The key 
intermediate (a protected dipeptide), was successfully prepared starting 
from L-valine and L-proline benzyl ester hydrochloride and subsequently 
employed to build two distinct portions of the final molecule. These  as 
partners in a Pd-catalyzed Suzuki coupling we obtain the desired API 
ravidasvir hydrochloride in high purity and overall yield (46%). This strategy 
reduced the number of steps compared to existing synthetic protocols. 
 
6.4  PhD student’s contribution 
My contribution to the work of the PhD project may be summarized as 
follow: after an initial study of the hypothetical synthetic strategies for the 
preparation of selected APIs, I identified suitable starting materials and 
reagents in terms of costs and commercial availability. I tested the reaction 
of the proposed way of synthesis in a gram scale and isolated all the 
product and byproduct for their full characterization (e.g. NMR, IR, ESI-MS). 
After this fundamental work I tried to change the experimental conditions in 
order to increase the yield of the synthetic steps and the purity of the 
obtained product. When the syntheses were adequately optimized I 
proceeded with a first scale up (100-200 g scale) to test if the synthetic 
protocol was robust and efficient for a future transfer to the industrial scale. 
Finally I contribute to write internal reports, scientific articles and patents of 
the selected APIs.  
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6.6 Abstract 
Active Pharmaceutical Ingredients (APIs) are a fundamental class of 
chemicals due to their important role in the human health. APIs are 
protected by intellectual property (IP), allowing the owners of the newly 
invented drug to have a temporary but complete exclusivity in terms of use, 
production and commercialization. The activity of the PhD is focused on the 
research of efficient and alternative synthesis of APIs, for which 
product/process patents are no longer valid or they are about to expire. The 
molecules selected for the research of alternative syntheses were 
vildagliptin (treatment of type 2 diabetes mellitus), fexofenadine 
hydrochloride (therapy for allergic rhinitis) and ravidasvir hydrochloride (a 
novel API, not yet approved, for the treatment of chronic hepatitis C). The 
aim of this work is to design alternative preparations for these selected 
APIs, optimising all the synthetic steps by adjusting reactions conditions 
and maximizing the yield of the processes and finally scaling up the whole 
syntheses to transfer the processes to the industrial scale. 
 
